[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 315
1. Rosenkrantz AB, Do RK, Hajdu CH: Imaging appearance of bulk fat within an oncocytic adrenocortical neoplasm, a rare and potentially malignant tumour. Br J Radiol; 2010 Oct;83(994):e204-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging appearance of bulk fat within an oncocytic adrenocortical neoplasm, a rare and potentially malignant tumour.
  • Oncocytic adrenocortical neoplasm is a rare adrenal tumour that usually follows a benign clinical course.
  • In some cases, however, these tumours have exhibited malignant behaviour.
  • Here, we present the first published case showing bulk fat within an oncocytic adrenocortical neoplasm on CT and MRI, a finding that mimics fat within an adrenal myelolipoma.
  • The distinction between these entities is important, as the current suggested management of an oncocytic adrenocortical neoplasm is resection with subsequent imaging surveillance.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Adrenal Cortex Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Proteins / metabolism. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1991 May-Jun;35(3):353-6 [2042437.001]
  • [Cites] Surg Today. 2007;37(7):612-7 [17593485.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Urol Clin North Am. 1997 Aug;24(3):603-22 [9275981.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Radiology. 1998 Jul;208(1):87-95 [9646797.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Jun;115(6):401-4 [17701888.001]
  • [Cites] Urol Oncol. 2008 Mar-Apr;26(2):198-201 [18312941.001]
  • [Cites] J Pediatr Surg. 2008 May;43(5):E1-3 [18485928.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):301-6 [18688642.001]
  • [Cites] Radiology. 2008 Dec;249(3):756-75 [19011181.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):299-303 [10790237.001]
  • [Cites] J Urol. 2001 Sep;166(3):985 [11490264.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):707-12 [11533079.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):95-112 [11809539.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Clin Imaging. 2003 Nov-Dec;27(6):426-30 [14585574.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] J Endocrinol Invest. 2006 Apr;29(4):298-302 [16699294.001]
  • [Cites] Hinyokika Kiyo. 1986 May;32(5):757-63 [3751804.001]
  • (PMID = 20846977.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC3473746
  •  go-up   go-down


2. Rodriguez FJ, Scheithauer BW, Erickson LA, Jenkins RB, Giannini C: Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case. Am J Surg Pathol; 2009 Jan;33(1):142-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case.
  • Ectopic adrenocortical neoplasms arising in the nervous system are very rare.
  • We encountered an intradural, extramedullary case of an adrenocortical neoplasm of indeterminate malignant potential affecting a spinal nerve root in the distal lumbar region of a 5-month-old girl.
  • The tumor in both resections had increased mitotic activity (5/10 high power fields) and MIB-1 labeling indices of 23% and 33% at initial resection and recurrence, respectively.
  • Both tumors demonstrated gains of chromosomes 5 and 12 by interphase cytogenetics, whereas insulin growth factor 2 was identified in the recurrent tumor by immunohistochemistry.
  • This report demonstrates that ectopic adrenocortical tumors in the nervous system may exhibit clinicopathologic and cytogenetic features suggestive of adrenocortical carcinoma.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1999 Dec;112(6):801-9 [10587703.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):429-35 [11949624.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Clin Endocrinol Metab. 1971 Feb;32(2):201-10 [4321503.001]
  • [Cites] Am J Med. 1981 May;70(5):1122-5 [7234878.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Virchows Arch. 1996 Mar;427(6):613-7 [8605573.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):650-4 [9527001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2776-9 [10443678.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):127-33 [16132517.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • (PMID = 18941403.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / T32 NS007494; United States / NINDS NIH HHS / NS / T32 NS07494-04
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS396174; NLM/ PMC3427599
  •  go-up   go-down


3. Kabayegit OY, Soysal D, Oruk G, Ustaoglu B, Kosan U, Solmaz S, Avci A: Adrenocortical oncocytic neoplasm presenting with Cushing's syndrome: a case report. J Med Case Rep; 2008;2:228

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical oncocytic neoplasm presenting with Cushing's syndrome: a case report.
  • INTRODUCTION: Oncocytic neoplasms occur in several organs and are most commonly found in the thyroid, kidneys and salivary glands.
  • Oncocytic neoplasms of the adrenal cortex are extremely rare and are usually non-functioning.
  • CASE PRESENTATION: We report the case of an adrenocortical oncocytic neoplasm with uncertain malignant potential in a 31-year-old man with Cushing's syndrome.
  • The patient had been operated on following diagnosis of a 7 cm adrenal mass.
  • CONCLUSION: Adrenocortical oncocytic neoplasms must be considered in the differential diagnosis of both functioning and non-functioning adrenal masses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1999 May 4;130(9):759-71 [10357696.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):299-303 [10790237.001]
  • [Cites] J Urol. 2001 Sep;166(3):985 [11490264.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2681-4 [1423199.001]
  • [Cites] Clin Imaging. 2003 Nov-Dec;27(6):426-30 [14585574.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Ann Diagn Pathol. 2005 Oct;9(5):295-7 [16198960.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):539-47 [1721751.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):565-9 [15717655.001]
  • (PMID = 18620603.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2481265
  •  go-up   go-down


Advertisement
4. Pereira RM, Michalkiewicz E, Pianovski MA, França SN, Boguszewski MC, Cat I, Lacerda Filho Ld, Sandrini R: [Treatment of childhood adrenocortical tumor]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):747-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood adrenocortical tumor].
  • [Transliterated title] Tratamento do tumor do córtex adrenal na infância.
  • Adrenocortical tumors (ACT) in children are uncommon.
  • However, the incidence of these tumors in Paraná is 15 times higher than that worldwide.
  • In our experience, disease stage I, absence of spillage during surgery and absence of intravenous thrombus are associated with better survival rates.
  • Preliminary data with the combination of etoposide, doxorubicin, cisplatin, and mitotane have shown that in some patients a complete remission is observed both of the tumor and metastasis.
  • Side effects due to these drugs are common and adrenal insufficiency may occur.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444357.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 36
  •  go-up   go-down


5. Lau SK, Weiss LM: The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol; 2009 Jun;40(6):757-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Weiss system for evaluating adrenocortical neoplasms: 25 years later.
  • The evaluation and categorization of adrenocortical neoplasms remain among the most challenging areas in adrenal pathology.
  • The Weiss system, first introduced 25 years ago, provides specific guidelines for differentiating adrenocortical adenoma from adrenocortical carcinoma and is considered the standard for determining malignancy in tumors of the adrenal cortex.
  • Considerable advances in the understanding of the pathology of adrenocortical neoplasia have occurred since delineation of the Weiss system, offering alternative approaches to the contemporary assessment of adrenocortical tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Adrenal Cortex / pathology. Adrenocortical Adenoma / pathology. Adrenocortical Carcinoma / pathology. Adult. Biopsy, Fine-Needle. Cell Nucleus / pathology. Child. Genes, Neoplasm. Humans. Immunohistochemistry. Mitosis. Necrosis. Neoplasm Invasiveness / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442788.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, Kenn W, Hahner S, Allolio B, Flentje M: Radiotherapy in adrenocortical carcinoma. Cancer; 2009 Jul 1;115(13):2816-23
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy in adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis.
  • Even after radical surgery, up to 85% of patients develop recurrent disease.
  • Ten articles were identified that covered radiotherapy in a total of 129 patients with ACC (64 patients received postoperative irradiation, and 65 patients received palliative therapy for advanced disease).
  • In those with advanced disease, a response to radiotherapy was observed in 57% of patients who received palliative radiotherapy.
  • Until better evidence is available, the authors recommended the following approach: Adjuvant radiotherapy to the tumor bed should be considered in patients at high risk for local recurrence (eg, incomplete/R1 resection); a total dose of >40 grays (Gy) with single fractions of 1.8 Gy to 2 Gy should be administered (including a boost volume to reach from 50 Gy to 60 Gy in individual patients); and radiotherapy in a palliative setting may be used for symptomatic metastases to bone, brain, or vena cava obstruction.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiotherapy. Adrenocortical Carcinoma / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local. Palliative Care. Radiation Injuries. Radiotherapy, Adjuvant. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402169.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


7. Geller JL, Azer PC, Weiss LM, Mertens RB: Pigmented adrenocortical carcinoma: case report and review. Endocr Pathol; 2006;17(3):297-304
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented adrenocortical carcinoma: case report and review.
  • Darkly pigmented adrenocortical neoplasms are rare tumors that are often referred to as "black adenomas," indicative of both their pigmented nature and their invariably benign clinical behavior in previously reported cases.
  • We herein describe an exceptional case of a malignant pigmented adrenocortical neoplasm, with late recurrence and metastasis.
  • At age 53, this female patient was diagnosed with Cushing's syndrome and underwent a laparoscopic right adrenalectomy, revealing a 3 cm well-circumscribed, darkly pigmented adrenocortical tumor.
  • The tumor exhibited several atypical histologic features and was diagnosed as an atypical pigmented adrenal cortical neoplasm of uncertain malignant potential.
  • At subsequent exploratory laparotomy, three separate tumor nodules exhibiting varying degrees of pigmentation and ranging from 2.2 to 3.3 cm maximum dimension were excised.
  • Histologically, the tumor nodules were consistent with local recurrence/metastasis of the patient's previously excised pigmented adrenocortical neoplasm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Pigmentation. Retroperitoneal Neoplasms / secondary
  • [MeSH-minor] Adrenalectomy. Cushing Syndrome / etiology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):334-41 [2435143.001]
  • [Cites] Hum Pathol. 1972 Sep;3(3):317-25 [5046900.001]
  • [Cites] Am J Clin Pathol. 1974 Jul;62(1):97-103 [4134750.001]
  • [Cites] Arch Pathol Lab Med. 1985 Feb;109(2):198-200 [3838445.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):265-80 [15163302.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1901-4 [15274373.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] J Natl Med Assoc. 2001 Jan;93(1):37-9 [12653379.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Mod Pathol. 1992 Jan;5(1):23-9 [1542635.001]
  • [Cites] Cancer. 1981 May 1;47(9):2153-61 [7226109.001]
  • [Cites] Arch Pathol Lab Med. 1991 Aug;115(8):813-5 [1863192.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):e125-8 [15387689.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):765-9 [2743269.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 17308367.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Szajerka A, Dziegiel P, Szajerka T, Zabel M, Winowski J, Grzebieniak Z: Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex. Anticancer Res; 2008 Sep-Oct;28(5B):2959-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex.
  • BACKGROUND: The aim of this study was to assess the metallothionein (MT), maintenance protein 2 (Mcm-2) and Ki-67 expressions in adrenocortical adenomas and carcinomas in comparison to normal tissue and evaluate the correlations between these markers of proliferation and between these markers and tumor diameter.
  • MATERIALS AND METHODS: The expression of MT, Mcm-2 and Ki-67 was assessed by immunochemistry in forty-eight adrenocortical adenomas, six adrenocortical carcinomas and eleven normal adrenal cortex tissue samples.
  • RESULTS: The expressions of MT, Mcm-2 and Ki-67 in the adrenocortical carcinomas were significantly higher than in the adenomas and normal tissue (p<0.05).
  • The levels of Mcm-2 were also higher in the adrenocortical adenomas compared to the normal tissue (p<0.05).
  • The Mcm-2 expression showed a positive correlation to the expression of MT in the adrenocortical carcinomas (r=0.773; p<0.05) and to the expression of Ki-67 in the adrenocortical adenomas (r=0.432; p<0.05).
  • The malignant tumor diameter was positively correlated with the MT and Mcm-2 expressions (r=0.766, p<0.05 and r=0.620, p<0.05, respectively).
  • CONCLUSION: The assessment of Mcm-2 expression seems to be of special importance as a marker of adrenocortical dysplasia and a reliable indicator of malignancy in suspicious masses of the adrenal cortex.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Cell Cycle Proteins / biosynthesis. Ki-67 Antigen / biosynthesis. Metallothionein / biosynthesis. Nuclear Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031940.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 9038-94-2 / Metallothionein; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


9. Gur C, Salmon A, Silvetski N, Gross DJ: [Adrenocortical carcinoma]. Harefuah; 2008 Jun;147(6):520-5, 574
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenocortical carcinoma].
  • Adrenocortical carcinoma (ACC) is a rare cancer with a generally poor prognosis.
  • In approximately 60% of cases the initial clinical manifestations are due to hypersecretion of adrenocortical hormones.
  • In the remainder of the cases the tumor is identified after imaging procedures for nonspecific complaints such as abdominal pain and nausea.
  • Medical therapy is employed in patients with unresectable or partially resected tumor and metastatic disease.
  • The current accepted treatment is a combination of Mitotane with chemotherapy, aimed at controlling hormonal hypersecretion and reduction of tumor mass.
  • In ACC patients there is wide variability in the course of the disease: some with metastatic disease will survive for more than 10 years, others succumb to the disease within months.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cushing Syndrome / etiology. Humans. Nausea / etiology. Neoplasm Staging. Pain / etiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693629.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


10. Tissier F: [Pathology of adrenocortical tumors: review and recent data]. Ann Endocrinol (Paris); 2009 Jun;70(3):179-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathology of adrenocortical tumors: review and recent data].
  • [Transliterated title] Anatomie pathologique des tumeurs corticosurrénaliennes de l'adulte : état des lieux et données récentes.
  • Most adrenocortical tumors are benign; adrenocortical carcinomas are rare but their prognosis is poor and their therapeutic is sparse.
  • In most adrenocortical tumors, the morphological approach brings sufficient elements to establish the differential diagnosis between a benign and a malignant tumor but in few cases, it is insufficient.
  • Moreover, morphology is limited for predicting prognosis of adrenocortical carcinomas.
  • These genetics findings already have repercussions for the patients in the development of molecular markers for diagnosis and prognosis and in the future they could help in the development of new morphological approaches, in particular immunohistochemical approaches.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Cyclin E / genetics. Gene Expression Regulation, Neoplastic. Insulin-Like Growth Factor II / genetics. Mitosis. Mutation. Necrosis / pathology. Neoplasm Metastasis / pathology. Pheochromocytoma / genetics. Pheochromocytoma / pathology. Prognosis. Tumor Suppressor Protein p53 / genetics. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298951.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cyclin E; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; 67763-97-7 / Insulin-Like Growth Factor II
  • [Number-of-references] 77
  •  go-up   go-down


11. Opocher G, Schiavi F, Cicala MV, Patalano A, Mariniello B, Boaretto F, Zovato S, Pignataro V, Macino B, Negro I, Mantero F: Genetics of adrenal tumors. Minerva Endocrinol; 2009 Jun;34(2):107-21
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of adrenal tumors.
  • Endocrinology pioneered the development of molecular medicine, but also the study of adrenal tumors had a great impact in this field.
  • Particularly important was the detection of genetics of tumors derived from the adrenal medulla, as well as that of those derived from the sympathetic and parasympathetic paraganglia.
  • Less well understood is the genetics of adrenal cortex tumors, in particular adrenocortical carcinoma, a rare and particularly aggressive disease.
  • There are only a few examples of hereditary transmission of adrenocortical carcinoma, but the analysis of low penetrance genes by genome wide association study may enable us to discover new genetic mechanisms responsible for adrenocortical-derived tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Biomarkers, Tumor / genetics. Mutation. Pheochromocytoma / genetics
  • [MeSH-minor] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Genetic Predisposition to Disease. Genomics. Humans. Neoplasm Proteins / genetics. Paraganglioma / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471236.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 81
  •  go-up   go-down


12. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC: Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer; 2005 Sep;45(3):265-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology, clinical characteristics, and management of adrenocortical tumors in children.
  • Childhood adrenocortical tumors (ACT) are very aggressive endocrine neoplasms whose incidence is quite low.
  • In recent years, however, new information has been derived from the International Pediatric Adrenocortical Tumor Registry (IPACTR), and new clues to its pathogenesis have emerged.
  • Two-thirds of patients have resectable tumors.
  • Cisplatin-based chemotherapy with mitotane is indicated for unresectable or metastatic disease, although its impact on overall outcome is slight.
  • In childhood ACT, age, tumor size, and tumor resectability are the most important prognostic indicators.
  • Outcome is stage-dependent; patients with small, resectable tumors have survival rates in excess of 80%, whereas the outcome for patients with unresectable disease is dismal.
  • Patients with large, resectable tumors have an intermediate outcome.
  • [MeSH-major] Adrenal Cortex Neoplasms
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Hormonal / therapeutic use. Child. Child, Preschool. Genes, p53 / genetics. Humans. Infant. Mitotane / therapeutic use. Mutation. Neoplasm Staging. Research. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15747338.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 71907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Number-of-references] 83
  •  go-up   go-down


13. Carden CP, Frentzas S, Langham M, Casamayor I, Stephens AW, Poondru S, Wheaton J, Lippman SM, Kaye SB, Kim ES: Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors.
  • IGF-1R blockade increases apoptosis and reduces tumor growth in preclinical models.
  • METHODS: Patients (pt) with advanced solid tumours were enrolled to determine safety, tolerability, maximum tolerated dose, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961354.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD, Beuschlein F: Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology; 2008 Mar;149(3):1314-22
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
  • Recent evidence suggests the existence of a stem cell-like subpopulation of cells in hematological and solid tumor entities, which determine the malignant phenotype of a given tumor through their proliferative potential and chemotherapy resistance.
  • Herein we demonstrate the presence of SP cells in a variety of adrenal specimens, including primary cultures of human adrenocortical tumors and normal adrenal glands as well as established human and murine adrenocortical cancer cell lines by fluorescence-activated cell sorter analysis and confocal microscopy.
  • On a functional level, SP cells from the human adrenocortical tumor cell line NCI h295R revealed an expression pattern consistent with a less differentiated phenotype, including lower expression of steroidogenic enzymes such as steroid acute regulatory protein (StAR) and side-chain cleavage enzyme (P450scc) in comparison with non-SP cells.
  • Similarly to the baseline growth kinetics, no survival benefit was evident in SP cells after treatment with cytotoxic agents commonly used in adrenocortical carcinomas.
  • Taken together, these findings provide evidence that Hoechst dye exclusion, in contrast to what has been reported for other tumor entities, is not a major tumor stem cell defining marker in adrenocortical NCI h295R tumor cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Neoplastic Stem Cells / cytology
  • [MeSH-minor] Adrenal Glands / cytology. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cell Cycle / physiology. Cell Differentiation / physiology. Cell Line, Tumor. Cell Proliferation. Cholesterol Side-Chain Cleavage Enzyme / metabolism. Coloring Agents. Drug Resistance, Neoplasm / physiology. Humans. Phenotype. Phosphoproteins / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063677.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Coloring Agents; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; EC 1.14.15.6 / Cholesterol Side-Chain Cleavage Enzyme
  •  go-up   go-down


15. Strosberg JR, Hammer GD, Doherty GM: Management of adrenocortical carcinoma. J Natl Compr Canc Netw; 2009 Jul;7(7):752-8; quiz 759
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adrenocortical carcinoma.
  • Adrenocortical carcinomas (ACCs) are rare tumors that arise from the cortex of the adrenal gland with an incidence 1 to 2 per million.
  • The rarity of this tumor translates into a paucity of experience in managing patients in most medical centers.
  • This article describes the basic diagnostic and prognostic issues in adrenal cancer management, and presents detailed rationales for therapeutic management.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Catecholamines / analysis. Chemotherapy, Adjuvant. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Diagnostic Imaging. Humans. Hydrocortisone / analysis. Metanephrine / analysis. Mitotane / therapeutic use. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19635227.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Catecholamines; 5001-33-2 / Metanephrine; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


16. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA, Mendonca BB, Latronico AC: Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab; 2008 Sep;93(9):3524-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors.
  • BACKGROUND: Adrenocortical tumors are heterogeneous neoplasms with incompletely understood pathogenesis.
  • IGF-II overexpression has been consistently demonstrated in adult adrenocortical carcinomas.
  • OBJECTIVES: The objective of the study was to analyze expression of IGF-II and its receptor (IGF-IR) in pediatric and adult adrenocortical tumors and the effects of a selective IGF-IR kinase inhibitor (NVP-AEW541) on adrenocortical tumor cells.
  • PATIENTS: Fifty-seven adrenocortical tumors (37 adenomas and 20 carcinomas) from 23 children and 34 adults were studied.
  • Cell proliferation and apoptosis were analyzed in NCI H295 cells and a new cell line established from a pediatric adrenocortical adenoma.
  • RESULTS: IGF-II transcripts were overexpressed in both pediatric adrenocortical carcinomas and adenomas.
  • Otherwise, IGF-II was mainly overexpressed in adult adrenocortical carcinomas (270.5 +/- 130.2 vs. 16.1 +/- 13.3; P = 0.0001).
  • IGF-IR expression was significantly higher in pediatric adrenocortical carcinomas than adenomas (9.1 +/- 3.1 vs. 2.6 +/- 0.3; P = 0.0001), whereas its expression was similar in adult adrenocortical carcinomas and adenomas.
  • IGF-IR expression was a predictor of metastases in pediatric adrenocortical tumors in univariate analysis (hazard ratio 1.84; 95% confidence interval 1.28-2.66; P = 0.01).
  • CONCLUSION: IGF-IR overexpression was a biomarker of pediatric adrenocortical carcinomas.
  • Additionally, a selective IGF-IR kinase inhibitor had antitumor effects in adult and pediatric adrenocortical tumor cell lines, suggesting that IGF-IR inhibitors represent a promising therapy for human adrenocortical carcinoma.
  • [MeSH-major] Adenoma / genetics. Adrenal Cortex Neoplasms / genetics. Carcinoma / genetics. Insulin-Like Growth Factor II / genetics. Receptor, IGF Type 2 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Infant. Male. Middle Aged. Neoplasm Metastasis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18611974.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, IGF Type 2; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


17. Rodgers SE, Evans DB, Lee JE, Perrier ND: Adrenocortical carcinoma. Surg Oncol Clin N Am; 2006 Jul;15(3):535-53
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma.
  • ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival.
  • Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies.
  • Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma
  • [MeSH-minor] Beckwith-Wiedemann Syndrome / genetics. Biopsy, Needle. Humans. Hydrocortisone / blood. Insulin-Like Growth Factor II. Magnetic Resonance Imaging. Neoplasm Staging. Proteins / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882496.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IGF2 protein, human; 0 / Proteins; 67763-97-7 / Insulin-Like Growth Factor II; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 85
  •  go-up   go-down


18. Markou A, Tsigou K, Papadogias D, Kossyvakis K, Vamvakidis K, Kounadi T, Piaditis G: A unique case of a benign adrenocortical tumor with triple secretion of cortisol, androgens, and aldosterone: development of multiple sclerosis after surgical removal of the tumor. Hormones (Athens); 2005 Oct-Dec;4(4):226-30
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of a benign adrenocortical tumor with triple secretion of cortisol, androgens, and aldosterone: development of multiple sclerosis after surgical removal of the tumor.
  • We present a 39-year old female with a benign adrenal tumor characterized by autonomous secretion of cortisol, androgens, and aldosterone.
  • CT of the adrenals revealed a 2.5 x 3.0 cm tumor with characteristics of an adenoma on the left adrenal gland.
  • Further investigations revealed suppressed basal ACTH levels, loss of diurnal rhythm of cortisol, and failure to suppress on low dose dexamethasone suppression test, suggesting autonomous cortisol secretion by the tumor.
  • Complete clinical and biochemical remission of the disease was observed after left adrenalectomy.
  • Histology confirmed the presence of an adrenocortical adenoma.
  • The flare-up of an autoimmune disease (multiple sclerosis) postoperatively could be coincidental or possibly related to the high normalization of the high cortisol levels acting as a precipitating factor.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenalectomy / adverse effects. Adrenocortical Adenoma / pathology. Adrenocortical Adenoma / surgery. Multiple Sclerosis / etiology
  • [MeSH-minor] Adult. Aldosterone / secretion. Androgens / secretion. Biopsy, Needle. Female. Follow-Up Studies. Humans. Hydrocortisone / secretion. Immunohistochemistry. Neoplasm Staging. Risk Assessment

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613821.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Androgens; 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


19. Hanna AM, Pham TH, Askegard-Giesmann JR, Grams JM, Iqbal CW, Stavlo P, Moir CR: Outcome of adrenocortical tumors in children. J Pediatr Surg; 2008 May;43(5):843-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adrenocortical tumors in children.
  • PURPOSE: This study reviews adrenocortical tumors in children to determine factors that significantly affect outcome.
  • METHODS: An institutional review board-approved retrospective review from 1976 to 2005 identified 23 patients younger than 19 years old with histologic confirmation of adrenocortical carcinoma (ACC) and adenomas.
  • RESULTS: The mean age of the 23 children was 9.0 +/- 1.6 years; girls predominated (female-to-male ratio = 1.9:1) as did cancers (ACC 16, adenoma 7); tumor hormone production (74%); and advanced stage for disease (66%).
  • CONCLUSIONS: Children, especially females with ACC present with large advanced-staged tumors.
  • The high percentage of children with functioning tumors suggests earlier detection is possible.
  • [MeSH-major] Adenoma / mortality. Adenoma / surgery. Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adolescent. Adrenalectomy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485950.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pianovski MA, Cavalli LR, Figueiredo BC, Santos SC, Doghman M, Ribeiro RC, Oliveira AG, Michalkiewicz E, Rodrigues GA, Zambetti G, Haddad BR, Lalli E: SF-1 overexpression in childhood adrenocortical tumours. Eur J Cancer; 2006 May;42(8):1040-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SF-1 overexpression in childhood adrenocortical tumours.
  • We have recently shown that SF-1 is amplified in childhood adrenocortical tumours (ACT).
  • Conversely, the SF-1 protein was found to be overexpressed in all cases, compared to normal age-matched adrenal glands.
  • Furthermore, no significant correlation existed with histological grade or with the clinical manifestation or evolution of disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Homeodomain Proteins / genetics. Neoplasm Proteins / genetics. Receptors, Cytoplasmic and Nuclear / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574405.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA71907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NR5A1 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Steroidogenic Factor 1; 0 / Transcription Factors
  •  go-up   go-down


21. Zhang H, Bu H, Chen H, Wei B, Liu W, Guo J, Li F, Liao D, Tang Y, Zhang Z: Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):32-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors.
  • Most adrenocortical tumors (ACTs) can be diagnosed directly by a combination of morphologic features and clinical findings.
  • However, sometimes it may be difficult to distinguish ACTs from other neoplasms such as pheochromocytomas and some metastatic tumors, particularly for small biopsy specimens because they may be morphologically similar.
  • Expression of calretinin has recently been suggested as a valuable immunomarker for the differential diagnosis between ACTs and other tumors; however, its diagnostic value is still under debate.
  • To determine the diagnostic value of calretinin in Chinese patients with adrenocortical and non-ACTs, we employed both polyclonal and monoclonal anticalretinin to characterize the expression of calretinin in adrenal tissues and compared its expression with that of inhibin alpha, Melan-A, cytokeratin, or CD99 by immunohistochemistry in tissue microarrays and standard tissue sections of 414 specimens.
  • Our results revealed that calretinin was expressed by adrenocortical cells, but not by the other cells tested and the percentage of calretinin-positive ACTs reached 99% when stained with polyclonal antibodies, which was higher than that with monoclonal anticalretinin (91.3%), anti-Melan-A (90.3%), antiinhibin alpha (81.6%).
  • Furthermore, unlike anti-Melan-A that stained all metastatic malignant melanoma, anticalretinin did not recognize other tested tumors.
  • Therefore, immunohistologic staining with polyclonal anticalretinin is more sensitive than other antibodies tested for the diagnosis of ACTs.
  • Importantly, our data suggested that the fried-egg-like staining pattern, but not the mere cytoplasmic staining, was characteristic of anticalretinin staining in adrenocortical tissues.
  • Thus, the combinational characterization of calretinin (either by polyclonal or monoclonal antibody), inhibin alpha, and Melan-A expression is of great significance in the differential diagnosis of ACTs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091323.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 57285-09-3 / Inhibins
  •  go-up   go-down


22. Wright CB, Brennan L, Brophy P, Kirsh G, Shapiro M, Potter B, Giss S, Lindeman KE, Obial R, Fannin E: Adrenocortical tumor with left renal vein, vena cava and intrahepatic venous extension. J Cardiovasc Surg (Torino); 2008 Feb;49(1):79-81
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical tumor with left renal vein, vena cava and intrahepatic venous extension.
  • She proved, however, to have an adrenal cortical carcinoma which displaced the kidney, exhibiting vascular invasion within the gland and non-adherent extension into the vena cava, atrium, common hepatic vein and left renal vein, where some adherence was present.
  • This unusual tumor required extensive surgery for removal, including use of cardiopulmonary bypass, with good results.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Carcinoma, Renal Cell / diagnosis. Hepatic Veins / pathology. Kidney Neoplasms / diagnosis. Renal Veins / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adrenalectomy. Adult. Cardiopulmonary Bypass. Diagnosis, Differential. Female. Heart Atria / pathology. Humans. Neoplasm Invasiveness. Nephrectomy. Treatment Outcome. Vascular Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212691.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Fassnacht M, Allolio B: Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):273-89
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical management of adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy, and most of the diagnostic and therapeutic strategies are not fully established according to criteria of evidence-based medicine.
  • International Consensus Conference 2003 and networks like the European Network for the Study of Adrenal Tumours (ENSAT)) have significantly advanced the field.
  • In patients with suspected ACC a thorough endocrine and imaging work-up is followed by complete (Ro) resection of the tumour by an expert surgeon and initiation of adjuvant mitotane.
  • In advanced disease not amenable to radical resection, cytotoxic drugs will be added to mitotane.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / metabolism. Adrenal Cortex Hormones / physiology. Animals. Disease Progression. Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500769.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 100
  •  go-up   go-down


24. Pianovski MA, Maluf EM, de Carvalho DS, Ribeiro RC, Rodriguez-Galindo C, Boffetta P, Zancanella P, Figueiredo BC: Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. Pediatr Blood Cancer; 2006 Jul;47(1):56-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil.
  • BACKGROUND: Several reports refer to an increased frequency of adrenal cortex tumors (ACT) among children in Southern Brazil, yet all data have been derived from hospital-based registries.
  • PROCEDURE: We reviewed all death certificates that mentioned ACT or adrenal neuroblastoma (NB) and which were reported to the Paraná State Department of Health between 1998 and 2003, for individuals younger than 15 years who resided in the Curitiba metropolitan region.
  • The ratio of the adrenal NB and ACT age-adjusted mortality rates was 1.43.
  • CONCLUSIONS: Our investigation of population-based mortality confirms the evidence from hospital-based registries of a clustering of ACT in Southern Brazil.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16200634.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gil J, Kalembkiewicz M, Polak E, Kostecka-Matyja M: [Disseminated adrenocortical carcinoma: case report]. Pol Arch Med Wewn; 2007 Jul;117(7):317-21
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated adrenocortical carcinoma: case report].
  • [Transliterated title] Rozsiany rak kory nadnercza.
  • Adrenocortical carcinoma is a rare neoplasm occurring with a frequency of 1-2 cases per million.
  • This type of a tumor is slightly more frequent in women (58.6%) than in men (41.4%).
  • Etiology of adrenocortical carcinoma is still unclear, but a role of genetic and environmental factors has been largely considered.
  • The tumor size is still the best single predictor of prognosis.
  • Histopathology specimen from biopsy or obtained during operation should be stained for Melan A, which can confirm the adrenal origin of the tumor.
  • We presented the case of functioning adrenocortical cancer in 37-year-old patient who at time of diagnosis had 12 cm in diameter tumor of the left adrenal gland and metastases to the liver and lung.
  • In the article the symptoms associated with hormones produced by the carcinoma, diagnostics and treatment with regard to the progression of the disease have also been discussed.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966598.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


26. Terzolo M, Berruti A: Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes; 2008 Jun;15(3):221-6
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjunctive treatment of adrenocortical carcinoma.
  • PURPOSE OF REVIEW: Description of the adjunctive treatment strategies in patients with adrenocortical carcinoma after complete surgical resection.
  • RECENT FINDINGS: A retrospective analysis showing that adjuvant mitotane may prolong recurrence-free survival in a large cohort of patients with radically resected adrenocortical carcinoma has recently been published.
  • SUMMARY: Radical surgical resection of adrenocortical carcinoma offers the best chance for prolonged recurrence-free survival; however, a significant number of patients without objective and biochemical evidence of residual tumor after surgery are destined to relapse.
  • Mitotane, an analogue of the insecticide dichlorodiphenyltrichloroethane, has been used for treatment of advanced adrenocortical carcinoma since the 1960s, but its use as an adjunctive postoperative measure has remained controversial.
  • The recent demonstration that mitotane treatment following macroscopically complete removal of adrenocortical carcinoma was associated with beneficial effects on outcome in a well designed, multicenter, international study should renew interest in adjuvant mitotane therapy.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Mitotane / adverse effects. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chemotherapy, Adjuvant / adverse effects. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Humans


27. Allolio B, Fassnacht M: Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab; 2006 Jun;91(6):2027-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical review: Adrenocortical carcinoma: clinical update.
  • CONTEXT: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with incompletely understood pathogenesis and poor prognosis.
  • Patients present with hormone excess (e.g. virilization, Cushing's syndrome) or a local mass effect (median tumor size at diagnosis > 10 cm).
  • The following search terms were used in varying combinations: adrenal, adrenocortical, cancer, carcinoma, tumor, diagnosis, imaging, treatment, radiotherapy, mitotane, cytotoxic, surgery.
  • EVIDENCE SYNTHESIS: Tumors typically appear inhomogeneous in both computerized tomography and magnetic resonance imaging with necroses and irregular borders and differ from benign adenomas by their low fat content.
  • Hormonal analysis reveals evidence of steroid hormone secretion by the tumor in the majority of cases, even in seemingly hormonally inactive lesions.
  • Histopathology is crucial for the diagnosis of malignancy and may also provide important prognostic information.
  • Local recurrence is frequent, particularly after violation of the tumor capsule.
  • Surgery also plays a role in local tumor recurrence and metastatic disease.
  • In advanced disease, the most promising therapeutic options (etoposide, doxorubicin, cisplatin plus mitotane, and streptozotocin plus mitotane) are currently being compared in an international phase III trial (www.firm-act.org).
  • Adjuvant treatment options after complete tumor removal (e.g. mitotane, radiotherapy) are urgently needed because postoperative disease-free survival at 5 yr is only around 30%, but options have still not been convincingly established.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy
  • [MeSH-minor] Follow-Up Studies. Humans. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551738.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 156
  •  go-up   go-down


28. Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA, Schott M: Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf); 2006 Aug;65(2):215-22
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare malignancy associated with a dismal prognosis.
  • DESIGN/PATIENTS: Autologous DCs were pulsed with autologous tumour lysate (TL).
  • Fusion of DCs with tumour cells was based on a polyethylene glycol method.
  • Clinical response was monitored by CT scan of tumour mass and measurement of angiogenic factors.
  • The DC/tumour cell fusion efficacy was approximately 45% as shown by double positive staining for ACTH receptor and DC-specific CD83.
  • Although angiogenic serum markers could be stabilized, no impact on tumour growth could be observed.
  • CONCLUSION: Our data demonstrate that autologous dendritic cells induce antigen-specific Th1 immunity in adrenocortical carcinoma.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / therapy. Cancer Vaccines / administration & dosage. Dendritic Cells / transplantation
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Fatal Outcome. Flow Cytometry. Humans. Hybridomas. Hypersensitivity, Delayed / immunology. Injections. Male. Microscopy, Electron. Middle Aged. Mitotane / therapeutic use. Treatment Failure

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886963.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 78E4J5IB5J / Mitotane
  •  go-up   go-down


29. Fassnacht M, Wittekind C, Allolio B: [Current TNM classification systems for adrenocortical carcinoma]. Pathologe; 2010 Sep;31(5):374-8
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current TNM classification systems for adrenocortical carcinoma].
  • Adrenocortical carcinoma (ACC) is a rare malignancy and often difficult to diagnose.
  • Therefore, the European Network for the Study of Adrenal Tumours (ENSAT) developed a revised staging system, the superiority of which was recently confirmed in an independent American cohort.
  • In the ENSAT classification, stage I (tumors ≤ 5 cm) and II (tumors < 5 cm) are non-infiltrating tumors without positive lymph nodes and distant metastases.
  • Stage III is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or venous tumor thrombus.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adrenal Cortex / pathology. Cohort Studies. Disease Progression. Humans. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology. Neoplastic Cells, Circulating. Prognosis. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):663-7; discussion 668 [1413834.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):713-9 [20044246.001]
  • [Cites] Eur Urol. 2010 Oct;58(4):609-15 [20580485.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer. 2002 May 1;94(9):2511-6 [12015777.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89 [19500769.001]
  • [Cites] World J Surg. 2006 May;30(5):872-8 [16680602.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):765-9 [2743269.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32 [20668036.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Br J Cancer. 1994 May;69(5):947-51 [8180029.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 20703482.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Lee SS, Baek KH, Lee YS, Lee JM, Kang MI, Cha BY, Lee KW, Son HY, Kang SK: Subclinical Cushing's syndrome associated with an adrenocortical oncocytoma. J Endocrinol Invest; 2008 Jul;31(7):675-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclinical Cushing's syndrome associated with an adrenocortical oncocytoma.
  • Oncocytoma is a neoplasm that can arise in several organs, and it has been more commonly described in the kidney, salivary gland and thyroid.
  • Oncocytoma arising in the adrenal gland is a rare finding.
  • Moreover, functioning adrenocortical oncocytoma is exceptionally rare.
  • A 47-yr-old man was incidentally discovered to have a right adrenal mass.
  • The patient had no clinical features suggestive of increased adrenal function.
  • Right adrenalectomy was performed, and this revealed a well-circumscribed dark-brown tumor that measured 2.4x2.2 cm.
  • The tumor consisted almost exclusively of large eosinophilic and epitheloid cells whose cytoplasm was packed with eosinophilic granulations, which corresponded to the numerous mitochondria confirmed on electron microscopy.
  • This is a rare case of subclinical Cushing's syndrome that was caused by adrenocortical oncocytoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology. Cushing Syndrome / pathology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):222-8 [11556749.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Am J Clin Pathol. 1995 Oct;104(4):382-90 [7572786.001]
  • [Cites] N Engl J Med. 1985 May 23;312(21):1371-5 [3990735.001]
  • [Cites] Ann Diagn Pathol. 2005 Oct;9(5):295-7 [16198960.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Clin Imaging. 2003 Nov-Dec;27(6):426-30 [14585574.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):539-47 [1721751.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Tumori. 1998 May-Jun;84(3):403-7 [9678626.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):457-61 [12656667.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):151-3 [10396247.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Urology. 1997 Apr;49(4):624-8 [9111640.001]
  • [Cites] Medicine (Baltimore). 1965 Jan;44:37-79 [14264352.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):407-9 [8626901.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] Am J Med. 1981 Nov;71(5):855-75 [6272575.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):718-21 [17091483.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):603-10 [15260851.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2681-4 [1423199.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Jan;48(1):89-97 [9509073.001]
  • [Cites] Obstet Gynecol. 2001 Nov;98(5 Pt 2):916-8 [11704201.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Hinyokika Kiyo. 1986 May;32(5):757-63 [3751804.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3173-6 [8784064.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(6):533-7 [1281594.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2367-75 [11994389.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Arch Esp Urol. 1999 Jun;52(5):525-8 [10427894.001]
  • [Cites] Nat Clin Pract Urol. 2006 Nov;3(11):618-21 [17088930.001]
  • (PMID = 18787391.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Synaptophysin; 0 / inhibin A; 57285-09-3 / Inhibins; 68238-35-7 / Keratins; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


31. Yavascaoglu I, Yilmaz M, Kordan Y: Cardiac and caval invasion of left adrenocortical carcinoma. Urol Int; 2008;81(2):244-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac and caval invasion of left adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare and highly malignant neoplasm.
  • We present the case of a 51-year-old male patient with a left-sided ACC admitted to hospital with ipsilateral flank pain, weight loss, difficulty in breathing, abdominal discomfort and swelling and bilateral leg edema.
  • Thoracoabdominal computed tomography revealed a huge adrenal mass with obvious tumor thrombus involvement of the inferior vena cava and right atrium.
  • This is the first report describing caval and opposite side renal vein invasion of a left-sided ACC treated with grafting of the vessels.
  • Histopathological examination of the tumors confirmed the diagnosis of ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Heart Atria / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18758230.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Blanes A, Diaz-Cano SJ: DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Hum Pathol; 2006 Oct;37(10):1295-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
  • Monoclonal adrenocortical lesions show inverse correlation between proliferation and apoptosis, with proliferation being the single most important criterion of malignancy in adrenal lesions.
  • No study yet has evaluated the variability of proliferation regarding the clonal pattern and diagnosis in adrenocortical nodular hyperplasias (ACNHs), adrenocortical adenomas (ACAs), and adrenocortical carcinomas (ACCs).
  • Statistics included analysis of variance/Student t tests regarding the clonal patterns and diagnosis.
  • Cell kinetic heterogeneity is the hallmark of adrenocortical neoplasms: tetraploid/hypertetraploid cell accumulation characterizes monoclonal lesions (suggesting nondisjunctional mitoses), whereas heterogeneously distributed mitotic figures and decreased diploid percentage define ACCs.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Adenoma / genetics. Adrenocortical Carcinoma / genetics. DNA, Neoplasm / analysis
  • [MeSH-minor] Apoptosis. Cell Nucleus / genetics. Cell Nucleus / pathology. Cell Proliferation. Clone Cells. Disease Progression. Flow Cytometry. Humans. Hyperplasia. Image Cytometry. Ki-67 Antigen / metabolism. Kinetics. Mitotic Index. Polyploidy. X Chromosome Inactivation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949934.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Ki-67 Antigen
  •  go-up   go-down


33. Aiba M, Fujibayashi M: Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol; 2005;16(1):13-22
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
  • A great majority of adrenocortical tumors are benign, and many adrenocortical carcinomas (ACC) are obviously malignant at presentation.
  • The histopathological diagnosis of ACC is occasionally difficult, particularly with stage I and stage II disease.
  • Histopathological prognostic factors of ACC have not been fully established because of the rarity of the disease.
  • These special type tumors include pediatric adrenocortical tumors, oncocytomas, and aldosterone-producing tumors of pure zona glomerulosa type.
  • Then we present three cases with unusual small adrenocortical tumors.
  • One patient had an unequivocal ACC showing metastatic disease.
  • The third was a pediatric patient with a tumor showing a nodule-in-nodule pattern with insulin-like growth factor II expression.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic. Adult. Aged. Aged, 80 and over. Aldosterone / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Infant. Insulin-Like Growth Factor II / metabolism. Male. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):10731-4 [2040591.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):867-81 [12826878.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):141-8 [12165663.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Surgery. 1992 Dec;112(6):981-6 [1360713.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):175-8 [9024511.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Endocr Pathol. 2003 Summer;14(2):107-16 [12858000.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):273-8 [15028030.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Acta Pathol Jpn. 1979 Mar;29(2):177-82 [552791.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):334-40 [1652202.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2048-56 [10843195.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):742-51 [12920217.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:1-53 [1736241.001]
  • [Cites] Am J Pathol. 1981 Jun;103(3):404-10 [7195152.001]
  • [Cites] Am J Pathol. 1986 Dec;125(3):431-5 [2432790.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 16000842.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


34. Arvanitis LD, Pitelka LA, Gattuso P: Adrenocortical carcinoma presenting with a peritoneal effusion. Diagn Cytopathol; 2010 Jul;38(7):514-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma presenting with a peritoneal effusion.
  • In this report, we describe the fine-needle aspiration findings of a case of adrenocortical carcinoma (ACC) that spread to the peritoneal cavity in an 80-year-old female.
  • Although ACC is the most common malignant neoplasm of the adrenal gland, its metastatic spread to the peritoneal cavity is exceptionally unusual.
  • [MeSH-major] Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / pathology. Ascitic Fluid / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19941369.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Blanes A, Diaz-Cano SJ: Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol; 2007 Mar;127(3):398-408

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability.
  • This study compared 3 systems and a newly designed stepwise discriminant diagnostic system (SDDS) to assess accuracy, reproducibility, and reliability in adrenocortical nodular hyperplasia (ACNH; n = 82), adenoma (ACA; n = 78), and carcinoma (ACC; n = 32) (diagnoses according to World Health Organization criteria; median follow-up, 135 months).
  • In cross-validations, we studied cortex appearance, growth pattern, cytoplasmic features, nuclear parameters, mitotic figure counting (MFC), necrosis, invasion, and stromal-inflammatory reactions.
  • The SDDS independent predictors were MFC/high-power field SD, anisokaryosis, cortex appearance, and stromal reaction, correctly classifying 100% of ACNH, 91% of ACA, and 88% of ACC cases.
  • MFC variability is the most important adrenocortical malignancy criterion.
  • Accurate malignancy diagnosis requires multiple variable evaluations, provided by SDDS (the most specific system) and the Weiss or van Slooten system (the most sensitive).
  • SDDS is the most useful system for distinguishing tumors from ACNH (myxoid stroma and anisokaryosis).
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Hyperplasia. Male. Middle Aged. Mitosis. Necrosis. Neoplasm Staging. Prognosis. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276949.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Martarelli D, Pompei P, Mazzoni G: Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197. Chemotherapy; 2009;55(6):425-32
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
  • BACKGROUND: In this study, we investigated the effect of CRM197 treatment in human adrenocortical carcinoma (AC) implanted in nude mice.
  • CRM197 is a non-toxic mutant of diphtheria toxin that binds heparin-binding epidermal growth factor-like growth factor (HB-EGF) which is implicated in the proliferative activity of several tumor cells.
  • AC tumors were implanted in nude mice and then treated with CRM197.
  • A treatment with CRM197 blocked growth, reduced angiogenesis and induced apoptosis in AC tumors implanted in nude mice.
  • CRM197 also inhibited invasion and migration of these tumor cells.
  • CONCLUSIONS: These data support the evidence for anticancer properties of CRM197 in AC tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents / pharmacology. Bacterial Proteins / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Movement / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation, Neoplastic. Heparin-binding EGF-like Growth Factor. Humans. Intercellular Signaling Peptides and Proteins / genetics. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Diphtheria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996587.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Proteins; 0 / HBEGF protein, human; 0 / Hbegf protein, mouse; 0 / Heparin-binding EGF-like Growth Factor; 0 / Intercellular Signaling Peptides and Proteins; 92092-36-9 / CRM197 (non-toxic variant of diphtheria toxin)
  •  go-up   go-down


37. Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd: Adrenocortical carcinoma: the influence of large vessel extension. Surgery; 2010 Dec;148(6):1057-64; discussion 1064
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: the influence of large vessel extension.
  • BACKGROUND: The impact of large vessel extension (LVE) as a prognostic factor for adrenocortical carcinoma (ACC) is not fully understood.
  • LVE was defined as vascular wall invasion or intraluminal extension of the neoplasm into the inferior vena cava or renal vein.
  • RESULTS: Multivariable regression analysis showed a significant association for decreased survival with Stage III and IV disease and LVE.
  • Patients with LVE had more functional neoplasms, greater preoperative serum hormone levels, and more positive margins than those without LVE.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Renal Veins / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 21134533.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Schlamp A, Hallfeldt K, Mueller-Lisse U, Pfluger T, Reincke M: Recurrent adrenocortical carcinoma after laparoscopic resection. Nat Clin Pract Endocrinol Metab; 2007 Feb;3(2):191-5; quiz 1 p following 195
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent adrenocortical carcinoma after laparoscopic resection.
  • A left adrenal mass of 6.5 cm by 7.5 cm was detected by a CT scan.
  • The patient underwent laparoscopic surgery to remove the tumor mass; histologic work-up revealed an adrenocortical carcinoma.
  • INVESTIGATIONS: In our department, laboratory work-up for endocrine activity was performed, as well as CT scans of the adrenal region, and FDG-PET scans in order to determine the extension of disease.
  • Histologic work-up of the removed tumor tissue was performed.
  • DIAGNOSIS: Recurrent adrenocortical carcinoma after laparoscopic adrenalectomy.
  • MANAGEMENT: In our department, 10 months after initial laparoscopic surgery, local tumor recurrence was treated by repeated extensive surgery, tumor-bed radiation therapy, and mitotane treatment.
  • The patient is now scheduled for polychemotherapy because of progressive metastatic disease revealed by follow-up CT and FDG-PET scanning in June 2006.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Adrenocortical Carcinoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237845.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


39. Hahner S, Fassnacht M: Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs; 2005 Apr;6(4):386-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane for adrenocortical carcinoma treatment.
  • Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis.
  • Mitotane is the only adrenal-specific agent available for the treatment of ACC, and although it has been used for several decades, many of its pharmacological properties, as well as its exact mechanism of action, remain to be fully elucidated.
  • Most published clinical reports of mitotane use are retrospective analyses of small numbers of patients, however, the collective findings of these studies indicate that mitotane has activity against ACC; in approximately 25% of cases mitotane led to an objective tumor regression and, in the majority of patients, control of hormone excess could be achieved.
  • [MeSH-major] Adrenocortical Carcinoma / drug therapy. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15898346.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 78E4J5IB5J / Mitotane
  • [Number-of-references] 112
  •  go-up   go-down


40. Tacon LJ, Soon PS, Gill AJ, Chou AS, Clarkson A, Botling J, Stalberg PL, Skogseid BM, Robinson BG, Sidhu SB, Clifton-Bligh RJ: The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors. J Clin Endocrinol Metab; 2009 Nov;94(11):4591-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The glucocorticoid receptor is overexpressed in malignant adrenocortical tumors.
  • CONTEXT: Adrenocortical carcinoma (ACC) is a rare tumor with a poor prognosis.
  • The Weiss score is the most widely accepted method for distinguishing an ACC from an adrenocortical adenoma (ACA); however, in borderline cases, accurate diagnosis remains problematic.
  • OBJECTIVE: Our objective was to study GR expression in adrenocortical tumors (ACTs) and to assess its utility as an adjunct to the Weiss score.
  • This finding was validated in an external cohort of ACTs, such that 14 of 18 ACCs (78%) demonstrated positive nuclear staining whereas 32 of 33 ACAs (94%) were negative (P < 0.001).
  • CONCLUSIONS: The immunohistochemical finding of nuclear GR staining identified ACCs with high diagnostic accuracy.
  • We propose that GR immunohistochemistry may complement the Weiss score in the diagnosis of ACC in cases that display borderline histology.
  • The possibility that GR is transcriptionally active in these tumors, and may therefore be a therapeutic target, requires further study.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Receptors, Glucocorticoid / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820023.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / NR3C1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Glucocorticoid
  •  go-up   go-down


41. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, Bartsch DK: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol; 2006 Apr;154(4):587-98
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.
  • OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare malignant neoplasm with extremely poor prognosis.
  • The molecular mechanisms of adrenocortical tumorigenesis are still not well understood.
  • The comparative analysis by cDNA microarrays of gene-expression patterns of benign and malignant adrenocortical tumors allows us to identify new tumor-suppressor genes and proto-oncogenes underlying adrenocortical tumorigenesis.
  • DESIGN AND METHODS: Total RNA from fresh-frozen tissue of 10 ACC and 10 benign adrenocortical adenomas was isolated after histologic confirmation of neoplastic cellularity of at least 85%.
  • The reference consisted of pooled RNA of 10 normal adrenal cortex samples.
  • Amplified RNA of tumor and reference was used to synthesize Cy3- and Cy5-fluorescently labeled cDNA in a flip-color technique.
  • RESULTS: The comparative analysis of gene expression revealed many genes with more than fourfold expression difference between ACC and normal tissue (42 genes), cortical adenoma and normal tissue (11 genes), and ACC and cortical adenoma (21 genes) respectively.
  • As confirmed by real-time PCR, the IGF2 gene was significantly upregulated in ACCs versus cortical adenomas and normal cortical tissue.
  • Genes that were downregulated in adrenocortical tumors included chromogranin B and early growth response factor 1.
  • CONCLUSIONS: Comprehensive expression profiling of adrenocortical tumors by the cDNA microarray technique is a very powerful tool to elucidate the molecular steps associated with the tumorigenesis of these ill-defined neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556722.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


42. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg; 2006 May;30(5):872-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
  • BACKGROUND: Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to 14% of adrenal incidentalomas.
  • The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC.
  • Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
  • The average tumor size was 12 cm (range: 2-36 cm), and only 4.2% were < or = 6 cm.
  • Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients.
  • Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage.
  • Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P < or = 0.002) and by multivariate analysis (P < or = 0.031).
  • CONCLUSIONS: Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level.
  • The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. SEER Program. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):65-72 [14733841.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):151-5 [8318407.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1431-3 [14519747.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2008-14 [14559954.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2214-22 [14522381.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] Med Care. 2003 Sep;41(9):1003-5 [12972839.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):13-8 [14685087.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] Am Surg. 2000 Jan;66(1):73-9 [10651352.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • (PMID = 16680602.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kajor M, Ziaja J, Król R, Ciupińska-Kajor M, Dobrosz Z, Heitzman M, Cierpka L: [Analysis of adrenocortical tumors morphology as regards their structure and potential malignancy]. Endokrynol Pol; 2006 Mar-Apr;57(2):136-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of adrenocortical tumors morphology as regards their structure and potential malignancy].
  • [Transliterated title] Analiza morfologii guzów kory nadnerczy pod wzgledem ich struktury i potencjalnej złośliwości.
  • INTRODUCTION: A consequence of diagnosis of adrenocortical carcinoma (ACC) is introduction of pharmacological therapy, precise monitoring of the patients and in some cases re-operation.
  • The aim of the study is to analyse morphology of adrenocortical tumours as regards their malignancy by use of criteria proposed by Weiss.
  • MATERIAL AND METHODS: 110 adrenocortical tumours in 107 patients were analysed (M 27.1%, F 72.9%; age 32 to 77 years, mean 55.2 +/- 9.7).
  • In 76 patients (71.0%) biochemical tests did not reveal hormonal hyperactivity of the tumour.
  • RESULTS: In routine histopatological examination ACC was diagnosed in 6 tumours (5.4%), adrenocortical adenoma (ACA) in 92 (83.6%) and adrenocortical hyperplasia in 12 (10.9%).
  • Nuclear grade III or IV was observed in 8 tumours (7.3%), mitotic rate > 5/50 high power fields in 6 (5.4%), atypical mitoses in 5 (4.5%), clear cells constituting < 25% of the tumour in 10 (9.1%), diffuse architecture in 8 (7.3%), necrosis in 16 (14.5%), veins infiltration in 4 (3.6%), sinusoids infiltration in 7 (6.3%), and tumour capsule infiltration in 5 (4.5%).
  • Among ACC tumours 4-9 features of malignancy were present, among ACA--0-3 features.
  • Statistical analysis revealed correlation between number of criteria proposed by Weiss and maximal tumour size (p < 0.05).
  • CONCLUSION: The structure and cell arrangement in adrenocortical adenoma are heterogeneous.
  • Application of criteria proposed by Weiss in histopathological examination of adrenocortical tumours can be useful in differentiating adrenocortical adenoma from carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / ultrastructure. Adrenocortical Adenoma / ultrastructure. Adrenocortical Carcinoma / ultrastructure. Biomarkers, Tumor / analysis. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773589.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Barzon L, Masi G, Pacenti M, Trevisan M, Fallo F, Remo A, Martignoni G, Montanaro D, Pezzi V, Palù G: Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch; 2008 Feb;452(2):181-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aromatase and estrogen receptors in human adrenocortical tumors.
  • We recently demonstrated that adrenocortical carcinoma cells express aromatase and estrogen receptors (ERs) and that 17beta-estradiol enhances adrenocortical cell proliferation.
  • To provide a clue to the role of estrogens in adrenal tumorigenesis, we investigated the expression profile of genes involved in sex steroid hormone production and activity in a large series of normal and neoplastic human adrenocortical tissues.
  • Quantitative reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry showed that ERalpha and ERbeta, androgen receptor (AR), and aromatase were expressed in the adrenal cortex and in adrenocortical tumors.
  • Western blot analysis revealed the presence of a truncated form of AR in adrenocortical tissues.
  • With respect to the normal adrenal cortex and adrenocortical adenomas, carcinomas were characterized by significantly lower ERbeta levels, ERalpha upregulation, and aromatase overexpression.
  • In agreement with our in vitro findings, the results of this study suggest that estrogens, locally produced by aromatase, could enhance adrenocortical cell proliferation though autocrine/paracrine mechanisms.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Aromatase / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adrenal Cortex / embryology. Adrenal Cortex / metabolism. Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Neoplasm / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2008 Aug;453(2):221-2 [18553103.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):795-802 [12457455.001]
  • [Cites] J Mol Endocrinol. 2005 Oct;35(2):245-56 [16216906.001]
  • [Cites] Endocrinology. 2005 Dec;146(12 ):5474-84 [16150902.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2215-22 [17405842.001]
  • [Cites] J Endocrinol Invest. 2005 May;28(5):459-63 [16075931.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):181-9 [14672738.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20591-7 [11927588.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1997 Sep;118(1):217-27 [9418012.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):345-53 [9867849.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):327-34 [16728566.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3509-12 [9329394.001]
  • [Cites] Mol Genet Metab. 2001 Sep-Oct;74(1-2):206-16 [11592817.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):847-52 [10690900.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9001-5 [17909000.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36418-29 [12842887.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2378-80 [7629233.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):853-67 [11861507.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):515-28 [11875111.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):537-51 [15369453.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2258-62 [11344236.001]
  • [Cites] J Steroid Biochem. 1986 Jul;25(1):1-9 [3747509.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):657-63 [15695411.001]
  • [Cites] J Endocrinol. 2002 Sep;174(3):R13-7 [12208674.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):39855-9 [11053406.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2326-42 [16709599.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):3010-9 [15181092.001]
  • [Cites] J Endocrinol. 1998 Dec;159(3):373-80 [9834454.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2597-600 [9661652.001]
  • [Cites] Am J Obstet Gynecol. 1984 Oct 1;150(3):326-7 [6486196.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Dec;83(12 ):4520-3 [9851803.001]
  • [Cites] Eur J Endocrinol. 2003 Oct;149(4):273-85 [14514341.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):649-52 [11158024.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Mol Cell Endocrinol. 1991 Jun;78(1-2):25-32 [1936523.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8167-75 [16091743.001]
  • (PMID = 18157729.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


45. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer; 2008 Dec 2;99(11):1900-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival.
  • In this study, we evaluate whether Snail is expressed in adrenocortical cancer (ACC) and if its expression is related to patient outcome.
  • Increasing evidence suggests that EMT plays a pivotal role in tumour progression and metastatic spread.
  • Seventeen of 26 (65%) ACC tumour samples expressed Snail when assessed by immunohistochemistry.
  • Snail expression was neither detected in normal adrenocortical tissue, nor in benign adrenocortical adenomas.
  • Survival rates were significantly decreased in Snail-positive tumours compared to Snail-negative tumours: 10 out of 16 vs one out of eight patients succumbed to disease after a median follow up of 14.5 and 28.5 months, respectively (P=0.03).
  • Patients with Snail-expressing ACCs presented in advanced disease (11 out of 12 vs 6 out of 14, P=0.01) and tend to develop distant metastases more frequently than patients with negative staining (7 out of 11 vs two out of eight, P=0.19).
  • Furthermore, Snail expression is associated with decreased survival, advanced disease and higher risk of developing distant metastases.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Cadherins / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Horm Res. 1997;47(4-6):279-83 [9167965.001]
  • [Cites] Physiol Rev. 1959 Jan;39(1):162-82 [13623432.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):252-8 [15668718.001]
  • [Cites] Dig Dis Sci. 2005 Jan;50(1):42-6 [15712635.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):772-6 [15917668.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):65-71 [16786124.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jun;36(6):357-63 [16766568.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5395-402 [17000672.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Breast Cancer Res. 2006;8(4):105 [16834762.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Histopathology. 2007 Aug;51(2):239-45 [17593212.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):865-74 [17914115.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1267-78 [11430829.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):78-84 [15272533.001]
  • [Cites] Development. 2004 Sep;131(17):4213-24 [15280211.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocrinology. 1990 Jun;126(6):3251-62 [2161753.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1303-9 [9137490.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5 [9694573.001]
  • (PMID = 19018264.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2600683
  •  go-up   go-down


46. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM: Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg; 2010 Jun;34(6):1380-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma.
  • BACKGROUND: Complete surgical resection is the mainstay of treatment for patients with adrenocortical cancer (ACC).
  • Seventeen patients underwent laparoscopic adrenalectomy (LA).
  • Median tumor size of those who underwent LA was 7.0 (range, 4-14) cm versus 12.3 (range, 5-27) cm for OR.
  • Recurrent disease in the laparoscopic group occurred in 63% versus 65% in the open group.
  • Mean time to first recurrence for those who underwent LA was 9.6 months (+/-14) versus 19.2 months (+/-37.5) in the open group (p < 0.005).
  • Fifty percent of patients who underwent LA had positive margins or notation of intraoperative tumor spill versus 18% of those who underwent OR (p = 0.01).
  • CONCLUSIONS: ACC continues to be a deadly disease, and little to no progress has been made from a treatment standpoint in the past 20 years.
  • Although feasible in many cases and tempting, laparoscopic resection should not be attempted in patients with tumors suspicious for or known to be adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Laparoscopy / contraindications
  • [MeSH-minor] Adolescent. Adrenalectomy / methods. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Surgery. 2005 Dec;138(6):1078-85; discussion 1085-6 [16360394.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):841-4 [15868253.001]
  • [Cites] Int J Urol. 2008 Apr;15(4):295-8 [18380814.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):516-21 [17704864.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1169-75 [15490057.001]
  • [Cites] Eur J Surg Oncol. 2008 Jan;34(1):67-70 [17532597.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1026-9 [15541121.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] Surgery. 1993 Dec;114(6):1120-4; discussion 1124-5 [8256217.001]
  • [Cites] J Endourol. 2008 May;22(5):985-9 [18377235.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2008 Feb;18(1):42-6 [18266573.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):405-11 [15820450.001]
  • [Cites] J Endocrinol Invest. 2008 Jun;31(6):531-6 [18591886.001]
  • (PMID = 20372905.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. van't Sant HP, Bouvy ND, Kazemier G, Bonjer HJ, Hop WC, Feelders RA, de Herder WW, de Krijger RR: The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology; 2007 Aug;51(2):239-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas.
  • AIMS: To compare two different multiparameter histopathological scoring indices and determine their prognostic value in patients presenting with adrenocortical carcinoma (ACC).
  • METHODS AND RESULTS: Seventy-nine adrenal cortical tumours were divided into adenomas (n = 17), non-metastatic carcinomas (n = 24) and carcinomas with metastatic disease and/or local recurrence during follow-up (n = 19) or at time of presentation (n = 19).
  • Time from diagnosis of ACC to development of metastatic disease was correlated with the WRI (P = 0.036, r = -0.350).
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Carcinoma / secondary. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593212.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Martarelli D, Pompei P, Baldi C, Mazzoni G: Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol; 2008 Apr;61(5):809-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice.
  • Adrenocortical carcinoma is a rare tumor of the adrenal gland which requires new therapeutic approaches as its early diagnosis is difficult and prognosis poor despite therapies used.
  • The aim of our study was to evaluate whether mebendazole may result therapeutically useful in the treatment of human adrenocortical carcinoma.
  • We analyzed the effect of mebendazole on human adrenocortical carcinoma cells in vitro and after implantation in nude mice.
  • Overall, these data suggest that treatment with mebendazole, also in combination with standard therapies, could provide a new protocol for the inhibition of adrenocortical carcinoma growth.
  • [MeSH-major] Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Mebendazole / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Humans. In Vitro Techniques. Male. Mice. Mice, Nude. Neoplasm Metastasis / prevention & control. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MEBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581752.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 81G6I5V05I / Mebendazole
  •  go-up   go-down


49. Zancanella P, Pianovski MA, Oliveira BH, Ferman S, Piovezan GC, Lichtvan LL, Voss SZ, Stinghen ST, Callefe LG, Parise GA, Santana MH, Figueiredo BC: Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J Pediatr Hematol Oncol; 2006 Aug;28(8):513-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
  • PURPOSE: To define a mitotane dose for pediatric patients with adrenocortical cancer (ACC) that maintains therapeutic plasma levels (TL) between 14 and 20 microg/mL and to verify its antitumor efficacy in association with 8 cycles of cisplatin, etoposide, and doxorubicin (CED).
  • Minor to partial tumor remission was found in 5 patients (<1 y) and complete remission was found in 2 patients.
  • Of the 3 patients who are alive at the time of report, 1 patient has been without disease for 16 months, and 2 patients have progressive disease.
  • All patients had recurrent metastatic disease (2 to 9 times).
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Mitotane / administration & dosage
  • [MeSH-minor] Administration, Oral. Child. Child, Preschool. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Monitoring / methods. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912591.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 78E4J5IB5J / Mitotane; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


50. Szabó PM, Tamási V, Molnár V, Andrásfalvy M, Tömböl Z, Farkas R, Kövesdi K, Patócs A, Tóth M, Szalai C, Falus A, Rácz K, Igaz P: Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene; 2010 May 27;29(21):3163-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed.
  • Sporadic adrenocortical tumours are common, but their pathogenesis is poorly elucidated.
  • In this study, we present a meta-analysis and review of gene expression microarray and comparative genome hybridization (CGH) studies performed to date on these tumours, including our own data.
  • Data of whole genome microarray studies from altogether 164 tumours (97 benign, 67 malignant) and 18 normal tissues were reclassified and reanalysed.
  • Significant gene sets and cytogenetic changes from publications without available genomic data were also examined including 269 benign, 215 malignant tumour and 30 normal tissues.
  • In our experimental study, 11 tumour and four normal samples were analysed by parallel mRNA and CGH profiling.
  • These pathways include novel, previously undescribed pathomechanisms of adrenocortical tumours, and associated gene products may serve as diagnostic markers of malignancy and therapeutic targets.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Comparative Genomic Hybridization. Genomics. Meta-Analysis as Topic
  • [MeSH-minor] Chromosome Aberrations. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Neoplasm / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305693.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Number-of-references] 50
  •  go-up   go-down


51. Shimony A, Bereza S, Shalev A, Gilutz H, Ilia R, Zahger D: Ventricular fibrillation as the presenting manifestation of adrenocortical carcinoma. Am Heart Hosp J; 2009;7(1):65-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ventricular fibrillation as the presenting manifestation of adrenocortical carcinoma.
  • We describe a case of a young adult in whom sudden cardiac death due to ventricular fibrillation was the presenting manifestation of an adrenocortical carcinoma.
  • The arrhythmia was precipitated by severe hypokalemia induced by the aldosterone-secreting tumor.
  • Sudden death has not been previously described as a manifestation of this adrenal neoplasm.
  • Unexplained persistent hypokalemia after resuscitated sudden death (especially when combined with hypertension( should prompt investigation for an underlying secondary hypertension, particularly adrenal pathology.
  • Adrenocortical carcinoma should be considered in the differential diagnosis of unexplained sudden death associated with unexplained hypokalemia.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenocortical Carcinoma / complications. Ventricular Fibrillation / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742438.001).
  • [ISSN] 1751-7168
  • [Journal-full-title] The American heart hospital journal
  • [ISO-abbreviation] Am Heart Hosp J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Benavente-Chenhalls LA, Vella A, Farley DR, Thompson GB, Grant CS, Richards ML: Malignant adrenal neoplasm masquerading as worrisome adrenal hemorrhage. Ann Surg Oncol; 2010 Oct;17(10):2710-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant adrenal neoplasm masquerading as worrisome adrenal hemorrhage.
  • BACKGROUND: Adrenal hemorrhage (AH) associated with adrenal neoplasm is rare.
  • This study assesses the clinical and pathological impact of AH in the setting of malignant adrenal neoplasm to establish management strategies.
  • MATERIALS AND METHODS: Patients admitted over a 25-year period with a diagnosis of AH and malignant adrenal neoplasm were retrospectively reviewed.
  • RESULTS: Malignant adrenal neoplasms were reported in 14 of 217 patients (6.4%) presenting with AH.
  • In 10 patients the adrenal tumor was metastatic.
  • Four patients had adrenocortical carcinoma (ACC).
  • All primary adrenal tumors were unilateral.
  • Computed tomography (n = 12) demonstrated adrenal masses ranging in size from 6.8 to 11.0 cm (mean, 9 cm).
  • CONCLUSION: Most patients with AH in the setting of malignant adrenal neoplasm had metastatic tumors to the adrenal glands.
  • These patients do not typically present in hemorrhagic shock, allowing for adequate preoperative evaluation for function and assessment for primary tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Hemorrhage / complications. Hemorrhage / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499282.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kvacheniuk AN: [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection]. Klin Khir; 2008 Mar;(3):34-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection].
  • Comparative efficacy of radical methods of surgical intervention for adrenocortical cancer (ACC) with lymphodissection (LD) and without it was studied.
  • Adrenalectomy (AE) with en bloc excision of tumor and systematic lymph nodes dissection (paranephral, left-side paraaortal and the right-side paracaval collectors) constitutes the optimal surgical procedure.
  • AE with the tumor en bloc excision without performance of LD may give the same expected efficacy only for I-II stages tumor, when it is impossible to confirm malignancy intraoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680995.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


54. Cham E, Watkin W, Goldschmidt R, Liu L: Fine needle aspiration cytology of adrenocortical oncocytic neoplasm: a case report. Acta Cytol; 2010 Jul-Aug;54(4):627-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adrenocortical oncocytic neoplasm: a case report.
  • BACKGROUND: Adrenocortical oncocytic neoplasms (AONs) are rare tumors that typically show marked nuclear pleomorphism and eosinophilic cytoplasm and are highly cellular on fine needle aspiration (FNA) smears.
  • These features, worrisome in conventional adrenocortical tumors, are not necessarily signs of malignancy in AONs.
  • Computed tomography showed a 10-cm, solid, left adrenal mass and a 21-cm complex cystic mass in the pelvis.
  • FNA of the adrenal mass showed hypercellular smears with dyscohesive cells having pleomorphic nuclei and abundant, granular cytoplasm.
  • Resection of the adrenal mass demonstrated an AON without definite malignant features.
  • CONCLUSION: On FNA, cells from an AON can be hypercellular and cytologically atypical, which can be pitfalls for a malignant diagnosis.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Fibroma / pathology. Humans. Middle Aged. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715669.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of stage III and IV adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs.
  • The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11-58).
  • The mean disease-free survival was 21.0 +/- 9.0 months (95% CI: 3.3-38.7).
  • The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively.
  • The mean disease-free survival time was 18.6 +/- 6.7 months (95% CI: 5.4-31.8).
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


56. Tan HS, Thai AC, Nga ME, Mukherjee JJ: Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome. Ann Acad Med Singapore; 2005 Apr;34(3):271-4
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome.
  • INTRODUCTION: At times, it may be difficult to differentiate early stage, low-grade adrenocortical carcinoma from benign adrenal adenoma.
  • CLINICAL PICTURE: A 53-year-old lady underwent right adrenalectomy for a 4-cm adrenocortical tumour causing Cushing's syndrome.
  • Histology revealed an adrenocortical adenoma.
  • Sixteen years later, she presented with a 14-cm adrenal tumour, again on the right side.
  • TREATMENT: She underwent surgical removal of the tumour.
  • Histology confirmed adrenocortical carcinoma.
  • OUTCOME: She died of metastatic disease 17 months later.
  • CONCLUSIONS: This case highlights the importance of long-term, systematic follow-up of patients treated for benign adrenal adenomas, especially if the tumour size exceeds 4 cm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Cushing Syndrome / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adrenocortical Adenoma / pathology. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902349.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


57. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Surgical resection is considered the most important treatment for this neoplasm.
  • Medical records of patients with the diagnosis of ADCC between 1990 and 2000 were reviewed.
  • Twelve per cent presented as an asymptomatic mass, 41 per cent as a functional tumor, and 47 per cent as a nonfunctioning tumor.
  • Older age, distant metastasis, nonoperative management, positive margins, advanced tumor stage, and venous invasion were significantly associated with worse overall actuarial survival.
  • Factors associated with a worse prognosis were stage of disease, nonoperative management, positive surgical margins, vascular invasion, and older age.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography. Female. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC: Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet; 2006 Jan;43(1):91-6
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation.
  • BACKGROUND: An inherited germline P53 mutation has been identified in cases of childhood adrenocortical carcinoma (ACT), a neoplasm with a high incidence in southern Brazil.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jun;82(12):1932-7 [10864200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Nat Struct Biol. 2002 Jan;9(1):12-6 [11753428.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):1248-55 [14654593.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24245-51 [15851479.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5358-62 [3409256.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1298-304 [8118819.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] Genet Epidemiol. 1999;16(1):15-39 [9915565.001]
  • [Cites] J Med Genet. 2004 May;41(5):354-9 [15121773.001]
  • (PMID = 16033918.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-71907
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2564508
  •  go-up   go-down


59. Gołkowski F, Buziak-Bereza M, Huszno B, Bałdys-Waligórska A, Stefańska A, Budzyński A, Okoń K, Chrzan R, Urbanik A: The unique case of adrenocortical malignant and functioning oncocytic tumour. Exp Clin Endocrinol Diabetes; 2007 Jun;115(6):401-4
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The unique case of adrenocortical malignant and functioning oncocytic tumour.
  • Adrenocortical oncocytoma is extremely rarely found.
  • Only a little more than thirty cases of adrenal oncocytoma, mainly nonfunctioning and benign, have been reported in the literature.
  • Adrenal mass 150 x 160 x 172 mm in size and enlarged periarterial lymph nodes were found in CT examination performed in 51-year-old male.
  • On laparotomy, the lesion was considered unresectable because of evident - confirmed by intraoperative ultrasound - tumour infiltration of the inferior caval vein.
  • The large biopsy specimen was obtained for histological examination in which tumour fulfilled criteria proposed by Bisceglia et al. for adrenocortical oncocytic borderline tumour.
  • The presented case appears to be the first malignant and functioning adrenocortical oncocytic tumour reported and confirms the complexity of its biology.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents, Hormonal / administration & dosage. Humans. Male. Middle Aged. Mitotane / administration & dosage. Neoplasm Proteins / metabolism. Venae Cavae / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701888.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Neoplasm Proteins; 78E4J5IB5J / Mitotane
  •  go-up   go-down


60. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J: Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res; 2007 Feb 1;13(3):844-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
  • PURPOSE: Allelic losses [loss of heterozygosity (LOH)] at the 17p13 locus are frequent (85%) in adrenocortical cancers.
  • The tumor suppressor gene TP53 is located at 17p13.
  • The aim of the study was to determine the frequency of TP53 somatic inactivating mutations in adrenocortical tumors with 17p13 LOH and their clinico-biological correlations.
  • EXPERIMENTAL DESIGN: TP53 somatic mutations, intragenic LOH (VNTR1 marker), and p53 overexpression were studied in 36 adrenocortical tumors with 17p13 LOH determined by Southern blot.
  • RESULTS: TP53 mutations were detected in 33% of the tumors, and VNTR1 LOH was present in 44% of the cases and did not always correlate with the presence of a TP53 mutation.
  • Only the TP53-mutant tumors exhibit a strong nuclear immunoreactivity.
  • TP53-mutant tumors were significantly larger than wild-type TP53 tumors (median tumor weight: 640 versus 185 g; P=0.02), were associated with a more advanced stage of tumor progression (MacFarlane stage IV; P=0.01), and had a shorter disease-free survival (P=0.03).
  • CONCLUSIONS: The finding that only a minority of adrenocortical tumors with 17p13 LOH had either a VNTR1 LOH or a TP53 mutation indicates that TP53 might not be the only or major tumor suppressor gene at 17p13 involved in adrenocortical cancer progression.
  • We suggest that a genetic instability of the 17p13 region, occurring early in adrenocortical cancer development, involves various genes located in this region.
  • TP53 might be only one of them, and its alteration by the occurrence of inactivating mutation is associated with the development of more aggressive tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Chromosomes, Human, Pair 17. Genes, p53. Loss of Heterozygosity. Minisatellite Repeats / genetics. Mutation
  • [MeSH-minor] Adult. Alleles. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Neoplasm / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


61. Mete O, Kapran Y, Güllüoğlu MG, Kiliçaslan I, Erbil Y, Senyürek YG, Dizdaroğlu F: Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. Virchows Arch; 2010 May;456(5):515-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.
  • In the evaluation of retroperitoneal masses, the practicing pathologist faces a dilemma when making a diagnosis based on histology given the often overlapping morphologic appearances of the adrenocortical carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).
  • However, its expression is not well-investigated in adrenal cortical tumors.
  • We examined CD10 expression in 47 surgically resected adrenocortical tumors (26 adenomas and 21 carcinomas) and compared with 20 clear cell RCCs and 25 HCCs.
  • Twenty HCCs (80%), 18 RCCs (90%), 11 adrenocortical carcinomas (52%), and 18 adrenocortical adenomas (69%) were positive for CD10.
  • Adrenocortical tumors displayed mainly cytoplasmic staining.
  • Four adrenocortical carcinomas and one adenoma also displayed the membranous staining pattern.
  • Despite the relatively small number of samples, our preliminary results revealed that adrenocortical tumors may express CD10 (Clone: 56C6).
  • The most important point from this paper is the fact that anti-CD10 expression has not been previously reported in adrenocortical carcinomas.
  • This suggests that CD10 does not seem to be a useful marker for discriminating clear cell RCCs from adrenocortical tumors since CD10 expression does not rule out the possibility of adrenocortical tumors.
  • This feature should be kept in mind when constructing an antibody panel for an epithelial tumor that involves the adrenal gland and kidney, especially in small biopsy specimens.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neprilysin / biosynthesis
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / immunology. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / immunology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2008 Jan;52(2):119-29 [17825057.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):77-82 [9916921.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1205-9 [14681320.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2178-83 [19318454.001]
  • [Cites] Horm Res. 2008;70(5):294-9 [18824868.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):206-11 [10823140.001]
  • [Cites] Pathol Int. 2009 Jan;59(1):38-43 [19121090.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):374-82 [10705818.001]
  • [Cites] J Pediatr Hematol Oncol. 2010 Jan;32(1):2-3 [20051779.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):413-4 [12604902.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Histopathology. 2004 Nov;45(5):460-7 [15500649.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):5-7 [11165004.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52 [16280664.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):289-97 [18852677.001]
  • [Cites] Pathology. 2009 Feb;41(2):191-3 [19152193.001]
  • (PMID = 20390424.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


62. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Jul;91(7):2665-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
  • CONTEXT: Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.
  • OBJECTIVE: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.
  • DESIGN: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.
  • RESULTS: Abnormal FDG uptake correctly indicated tumor recurrence in 10 patients.
  • CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. False Negative Reactions. Female. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621901.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R25 CA23944; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 54216; United States / NCRR NIH HHS / RR / M01-RR00042
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Montone KT, Rosen M, Siegelman ES, Fogt F, Livolsi VA: Adrenocortical neoplasms with myelolipomatous and lipomatous metaplasia: report of 3 cases. Endocr Pract; 2009 Mar;15(2):128-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical neoplasms with myelolipomatous and lipomatous metaplasia: report of 3 cases.
  • OBJECTIVE: To present pathologic and radiographic features of 3 patients with adrenocortical neoplasms-2 with uncertain malignant potential and 1 adenoma with areas of myelolipomatous and lipomatous metaplasia.
  • METHODS: We describe 3 patients who had adrenocortical neoplasms with foci of myelolipomatous and lipomatous metaplasia.
  • Two patients showed imaging findings compatible with adrenal myelolipoma.
  • Pathologically, 2 of the lesions were classified as adrenocortical neoplasms of uncertain malignant potential, and 1 lesion was classified as an adrenocortical adenoma.
  • All 3 lesions contained myelolipomatous foci throughout the neoplasm, and 2 of the tumors contained several pure lipomatous foci.
  • CONCLUSION: Adrenocortical neoplasms, including those associated with an uncertain malignant potential, may be associated with areas of myelolipomatous and lipomatous metaplasia.
  • Imaging studies may result in a false diagnosis of a benign adrenal myelolipoma and potential undertreatment in such patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / pathology. Lipomatosis / diagnosis. Metaplasia / diagnosis. Myelolipoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289323.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gumy-Pause F, Bongiovanni M, Wildhaber B, Jenkins JJ, Chardot C, Ozsahin H: Adrenocortical oncocytoma in a child. Pediatr Blood Cancer; 2008 Mar;50(3):718-21
Hazardous Substances Data Bank. ANDROSTENEDIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical oncocytoma in a child.
  • Adrenocortical oncocytoma is a rare epithelial tumor only described in adults.
  • We report the case of a 12-year-old female who presented a left adrenal mass with abdominal pain, fatigue, acne vulgaris, and elevation of the androstenedione and total testosterone.
  • A diagnosis of adrenocortical oncocytoma was made after detailed histological, immunohistochemical, and ultrastructural studies.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Acne Vulgaris / etiology. Adrenalectomy. Androstenedione / secretion. Child. Female. Humans. Neoplasm Proteins / analysis. Testosterone / secretion

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17091483.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione
  •  go-up   go-down


65. Tucci S Jr, Martins AC, Suaid HJ, Cologna AJ, Reis RB: The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J Urol; 2005 Dec;174(6):2338-42, discussion 2342
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of tumor stage on prognosis in children with adrenocortical carcinoma.
  • PURPOSE: We evaluated treatment outcomes in children with adrenocortical carcinoma.
  • In 27 of 28 patients without intracaval extension complete surgical excision was accomplished, while tumor resection combined with thrombectomy was carried out in 5 of 6 children with vascular invasion.
  • Children with incomplete excision of the tumor and/or stage IV disease received adjuvant chemotherapy.
  • RESULTS: Ultrasonography, computerized tomography and magnetic resonance imaging exhibited specificity of 100% in the diagnosis of vascular invasion, and sensitivity of 50%, 66% and 100%, respectively.
  • Patient age, tumor stage or size and vascular invasion were associated with survival in univariate analysis.
  • Tumor stage was the only independent factor associated with survival in multivariate analysis.
  • The overall 5-year survival rates according to tumor stage were 100% in stage I, 85% in stage II, 40% in stage III and 0% in stage IV.
  • Of 11 children with local recurrence only 2 were alive without disease at 96 and 204 months after reoperation with complete tumor excision.
  • Only 2 of 6 patients with vascular invasion were disease-free at 17 and 50 months.
  • A total of 10 children with stage IV disease treated with chemotherapy died within a median of 6 months.
  • CONCLUSIONS: Tumor stage was the most relevant prognostic factor for children with adrenocortical carcinoma.
  • Reoperation for local tumor recurrence and thrombectomy for inferior vena caval tumor invasion should be attempted whenever possible.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adolescent. Cardiopulmonary Bypass. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / etiology. Neoplasm Staging. Prognosis. Retrospective Studies. Sensitivity and Specificity. Survival Analysis. Thrombectomy. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280838.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med; 2007 Jun 7;356(23):2372-80
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane treatment for adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection.
  • METHODS: We performed a retrospective analysis involving 177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005.
  • RESULTS: Baseline features in the mitotane group and the control group from Italy were similar; the German patients were significantly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in the mitotane group.
  • CONCLUSIONS: Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Multivariate Analysis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Survival Analysis


67. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ: Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B; 2009 Jan;10(1):1-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare but highly malignant tumor, and its diagnosis is mostly delayed and prognosis is poor.
  • We report estrogen receptor (ER) expression in this tumor and our clinical experiences with 17 ACC cases.
  • Immunohistochemistry was used to detect ER expression in tumor samples from the 17 patients.
  • RESULTS: At the time of diagnosis, 4 tumors were classified as Stage I, 4 as Stage II, 3 as Stage III, and 6 as Stage IV.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):65-72 [14733841.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3583-5 [6861130.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Endocr Rev. 1987 Feb;8(1):29-43 [3549276.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1882-4 [2924327.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):791-805 [9735134.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • (PMID = 19198016.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2613956
  •  go-up   go-down


68. Karim RZ, Wills EJ, McCarthy SW, Scolyer RA: Myxoid variant of adrenocortical carcinoma: report of a unique case. Pathol Int; 2006 Feb;56(2):89-94
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid variant of adrenocortical carcinoma: report of a unique case.
  • Myxoid variant of adrenocortical carcinomas (ACC) are rare, there being only 11 cases in the literature to date.
  • Reported herein are the findings of a case, which in contrast to all previously reported myxoid ACC, was devoid of typical non-myxoid areas.
  • The patient was a 61-year-old man in whom a left adrenal mass was detected during investigation of Cushing's syndrome.
  • The adrenal was replaced by malignant cells and expanses of myxoid material.
  • The ultrastructural features of the cells were typical of adrenal cortical differentiation.
  • The differential diagnosis of myxoid ACC includes extraskeletal myxoid chondrosarcoma, chordoma, myxoid adenocarcinoma, myxoma, lipomatous tumors, nerve sheath tumors, smooth muscle tumors, gastrointestinal stromal tumor and other sarcomas.
  • The presence of myxoid material in a retroperitoneal lesion raises a broad differential diagnosis in which myxoid adrenocortical neoplasms should be included.
  • Clinicoradiological correlation may be helpful, but special stains, immunohistochemistry and ultrastructural examination may be necessary to establish the diagnosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Antigens, Neoplasm. Chordoma / diagnosis. Chordoma / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. MART-1 Antigen. Male. Microscopy, Electron. Middle Aged. Myxoma / diagnosis. Myxoma / pathology. Neoplasm Proteins / analysis. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / pathology. Synaptophysin / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445821.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / Synaptophysin; 0 / Vimentin
  •  go-up   go-down


69. Komissarenko IV, Rybakov SI, Kvacheniuk AN, Lazar' SI, Fedorova TI, Kovalenko AE, Mel'nik ND, Negrienko KV: [The role of computer tomography in differential diagnosis of benign and malignant tumors of the adrenals cortex]. Klin Khir; 2005 Jul;(7):42-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of computer tomography in differential diagnosis of benign and malignant tumors of the adrenals cortex].
  • Possibilities of computer tomography (CT) application for differential diagnosis of tumors of the adrenal cortex (TAC) were studied.
  • While the trustworthy signs of malignancy are absent, it is necessary to conduct morphological verification of the adrenal tumors nature using puncture biopsy and/or intraoperative express-cytological investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255222.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


70. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A, Terzolo M: Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer; 2008 Dec;15(4):1043-53
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
  • Seventeen consecutive patients who were treated with mitotane after radical resection of adrenocortical cancer (ACC) from 1999 to 2005 underwent physical examination, routine laboratory evaluation, monitoring of mitotane concentrations, and a hormonal work-up at baseline and every 3 months till ACC relapse or study end (December 2007).
  • Mitotane affected adrenal steroidogenesis with a more remarkable inhibition of cortisol and DHEAS than aldosterone.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromatography, High Pressure Liquid. Female. Humans. Hydrocortisone / metabolism. Hypothyroidism / etiology. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Survival Rate. Testosterone / metabolism. Young Adult

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824557.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 3XMK78S47O / Testosterone; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


71. Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, Kim JH, Bang SM, Kim JS, Lee JS: Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol; 2009 Mar;39(3):183-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
  • Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis.
  • Palliative chemotherapy can be considered in patients with metastatic disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / pathology. Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Indoles / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Humans. Male. Mitotane / administration & dosage. Radiotherapy, Adjuvant. Treatment Failure. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168875.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 78E4J5IB5J / Mitotane
  •  go-up   go-down


72. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B, Fassnacht M: Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab; 2008 Jun;93(6):2057-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
  • CONTEXT: Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis.
  • In advanced disease, mitotane given as monotherapy or combined either with etoposide, doxorubicin, and cisplatin or with streptozotocin is the recommended first-line therapy.
  • However, many patients have progressive disease despite treatment with these regimens.
  • MAIN OUTCOME MEASURE: We evaluated tumor response according to response evaluation criteria in solid tumors (RECIST) criteria after 12 wk of treatment.
  • Only one in 10 patients experienced a minor response (progression-free survival 8 months), whereas eight patients had progressive disease at the first staging.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Quinazolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Administration Routes. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Endocrinol Metab. 2008 Aug;93(8):3230. Ritte, Christian [corrected to Ritter, Christian]
  • (PMID = 18334586.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


73. Siriwong S, Shuangshoti S, Saritsiri S, Pak-art P, Khovidhunkit W, Snabboon T: Functioning adrenocortical carcinoma with superior vena cava and upper airway obstructions. J Med Assoc Thai; 2006 Sep;89(9):1511-5
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functioning adrenocortical carcinoma with superior vena cava and upper airway obstructions.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is one of the most aggressive endocrine malignancies with a dismal prognosis.
  • Typically, the tumor is large and has regional invasion or distant metastasis at initial presentation.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Airway Obstruction / pathology. Vena Cava, Superior / pathology
  • [MeSH-minor] Adult. Cushing Syndrome / diagnosis. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100393.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


74. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B: Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Nov;91(11):4501-4
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
  • CONTEXT: Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation.
  • OBJECTIVE: The objective of the study was investigation of adjuvant tumor bed irradiation in the treatment of ACC.
  • PATIENTS: The German ACC Registry (n = 285) was screened for patients who had received tumor bed radiotherapy in an adjuvant setting (no macroscopic evidence for residual disease after surgery).
  • Fourteen patients without distant metastases (World Health Organization stage I, one patient; stage II, seven; stage III, three; and stage IV, three) were matched with 14 patients for resection status, adjuvant mitotane treatment, stage, and tumor size.
  • MAIN OUTCOME MEASURE: Survival without local recurrence and disease-free survival was the main outcome measure.
  • However, disease-free and overall survival were not significantly different between the two groups.
  • CONCLUSION: These data from the largest series of ACC patients treated with adjuvant tumor bed irradiation suggest that radiotherapy is effective in reducing the high rate of local recurrence in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiotherapy. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / radiotherapy. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Humans. Middle Aged. Mitotane / therapeutic use. Radiotherapy / adverse effects. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2006 Nov;91(11):4250-2 [17088440.001]
  • (PMID = 16895957.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


75. Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM: Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg; 2010 Sep;395(7):955-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
  • PURPOSE: Various staging systems for adrenocortical carcinoma (ACC) have been proposed.
  • We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.
  • METHODS: A retrospective review of patients included in the University of Michigan ACC database from 2005 to 2009 was done; and stage, tumor grade, time to recurrence, and death were recorded and analyzed using the Cox regression and Kaplan-Meier survival curves.
  • There were 28 deaths; overall, tumor grade showed a significant difference in time to tumor recurrence (p = 0.011) and time to death (p = 0.004).
  • Time to death among stage 2 patients separated into those with high- and low-grade tumors reached statistical significance (p = 0.05), and notable but not statistically significant differences were identified in all stages.
  • Based on tumor grade and survival curves, modifications to the current ENSAT staging system were made.
  • CONCLUSION: Tumor grade plays a significant role in the outcome of patients with ACC.
  • High-grade tumors are associated with shorter disease-free intervals and shorter overall survival.
  • The proposed modification of the ENSAT staging system allows for incorporation of tumor grade when predicting overall survival.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / pathology. Neoplasm Recurrence, Local / mortality. Neoplasm Staging / trends

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2005 Dec;138(6):1078-85; discussion 1085-6 [16360394.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Eur J Cancer. 2010 Mar;46(4):713-9 [20044246.001]
  • [Cites] Oncologist. 2008 May;13(5):548-61 [18515740.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Surg Clin North Am. 2009 Oct;89(5):1255-67 [19836496.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] World J Surg. 2010 Jun;34(6):1380-5 [20372905.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer. 2008 Dec 1;113(11):3130-6 [18973179.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):668-76 [19147773.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Surgery. 1992 Dec;112(6):972-9; discussion 979-80 [1455322.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Ann Surg Oncol. 2010 Jan;17(1):263-70 [19851811.001]
  • (PMID = 20694732.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Fassnacht M, Allolio B: What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf); 2010 Nov;73(5):561-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
  • In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www.ENSAT.org/ACC.htm).
  • As many patients will suffer from tumor recurrence after seemingly complete removal of ACC, adjuvant treatment based on the individual risk status is recommended.
  • Key factors for risk assessment are tumor stage, resection status and the proliferation marker Ki67.
  • R1 resection) we recommend additional radiotherapy of the tumor bed.
  • In low/intermediate risk patients who cannot be included in this trial observation only can be justified in cases with a tumor diameter of <8 cm and no microscopic evidence for invasion of blood vessels or tumor capsule.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Humans. Ki-67 Antigen / metabolism. Mitotane / therapeutic use. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20738315.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 78E4J5IB5J / Mitotane
  •  go-up   go-down


77. Barzon L, Masi G, Fincati K, Pacenti M, Pezzi V, Altavilla G, Fallo F, Palù G: Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol; 2005 Nov;153(5):629-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical tumors may originate from the zona glomerulosa, zona fasciculata, or zona reticularis and be associated with syndromes due to overproduction of mineralocorticoids, glucocorticoids, or androgens respectively.
  • We report an unusual case of recurrent adrenocortical carcinoma (ACC), which seems to contradict the paradigm of functional adrenal zonation.
  • After removal of the tumor recurrence and eight cycles of chemotherapy with etoposide, doxorubicin and cisplatin, the patient presented again with ACC masses, but in association with overt Cushing's syndrome and normal aldosterone levels.
  • METHODS AND RESULTS: Extensive pathologic examination showed that this shift in steroid hormone production was paralleled by an attenuation of tumor cell atypia and polymorphism, whereas gene expression profile analysis demonstrated a change in expression of adrenal steroidogenic enzymes.
  • CONCLUSIONS: This case of recurrent ACC demonstrates that adrenocortical cells can reverse their differentiation program during neoplastic progression and change their specific hormone synthesis, as a consequence of modifications in the expression profile of steroidogenic enzymes and cofactors.
  • These findings, besides opening new perspectives to study adrenocortical cell plasticity and potential, demonstrate how conventional clinical and pathologic evaluation can be combined with genomic analysis in order to dissect thoroughly the biology of cancer.


78. Aubert S, Buob D, Leroy X, Devos P, Carnaille B, Do Cao C, Wemeau JL, Leteurtre E: [Weiss system: a still in-use diagnostic tool for the assessment of adrenocortical malignancy]. Ann Pathol; 2005 Dec;25(6):545-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weiss system: a still in-use diagnostic tool for the assessment of adrenocortical malignancy].
  • [Transliterated title] Le système de Weiss: un outil toujours d'actualité pour le diagnostic de malignité des tumeurs de la corticosurrenale.
  • Adrenocortical carcinomas are rare tumors.
  • In the absence of the gold standard that constitutes metastases, local invasion or recurrence, the diagnosis of malignancy may represent a great challenge for both clinicians and pathologists.
  • A more precise definition of the different microscopic criteria and the proposition of a modified Weiss system based on the most reliable criteria could help.
  • Besides, the Weiss system is of limited value for the diagnosis of malignancy in oxyphil tumors and children tumors of the adrenal cortex.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Adult. Child. Humans. Mitotic Index. Necrosis. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735978.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 55
  •  go-up   go-down


79. Reyes MA, Ciancio G, Singal R, Manoharan M: Adrenocortical carcinoma with tumor thrombus in the right hepatic vein. Int J Urol; 2006 Sep;13(9):1233-5
MedlinePlus Health Information. consumer health - Blood Clots.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma with tumor thrombus in the right hepatic vein.
  • Adrenocortical carcinoma is an unusual neoplasm with very poor prognosis.
  • Patients present with an abdominal mass often exceeding 5 cm or as a functional tumor.
  • Computed tomography is effective to demonstrate the neoplasm as an inhomogeneous adrenal lesion with irregular margins, and magnetic resonance imaging is helpful to visualize invasion into large vessels as well.
  • Reported herein is a case of large adrenocortical carcinoma with tumor thrombus extending into the right hepatic vein.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Hepatic Veins / pathology. Thrombosis / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984559.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


80. Ohwada S, Izumi M, Tanahashi Y, Kawate S, Hamada K, Tsutsumi H, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Combined liver and inferior vena cava resection for adrenocortical carcinoma. Surg Today; 2007;37(4):291-7
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver and inferior vena cava resection for adrenocortical carcinoma.
  • PURPOSE: Adrenocortical carcinoma (ACC) is a rare malignancy, usually diagnosed at an advanced stage when it has invaded or adhered to adjacent organs.
  • The 5-year disease-free survival rate was 16.7%.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / secondary. Adrenocortical Carcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Polytetrafluoroethylene. Survival Rate

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] World J Surg. 1998 Jun;22(6):605-11; discussion 611-2 [9597936.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):624-30; discussion 630-1 [12799333.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Urology. 2003 Jul;62(1):138-40 [12837443.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Surg Clin North Am. 2000 Feb;80(1):275-93, xii [10685153.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):63-71 [9915245.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Mar;125(3):526-32 [12658194.001]
  • [Cites] J Surg Oncol. 1994 Mar;55(3):160-4 [8176925.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] Surgery. 2006 Jan;139(1):15-27 [16364713.001]
  • [Cites] Ann Surg. 2004 May;239(5):712-9; discussion 719-21 [15082976.001]
  • [Cites] J Am Coll Surg. 1996 Dec;183(6):597-605 [8957462.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):471-9 [10749606.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):733-4 [11235750.001]
  • [Cites] Arch Surg. 1992 Mar;127(3):276-80 [1312817.001]
  • [Cites] Arch Surg. 1995 Jul;130(7):793-7 [7611873.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Am J Clin Oncol. 1991 Apr;14(2):170-4 [1709336.001]
  • [Cites] Br J Cancer. 1994 May;69(5):947-51 [8180029.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):339-46 [16498606.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • (PMID = 17387560.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


81. Bauditz J, Quinkler M, Beyersdorff D, Wermke W: Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound. Oncol Rep; 2008 May;19(5):1135-9
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound.
  • Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy whose pathogenesis and poor prognosis is poorly understood.
  • Computerized tomography (CT) and magnetic resonance imaging (MRI) are routinely performed for the imaging of the adrenal mass and for standard staging of the chest and abdomen as the lung and liver are the primary organs for metastasis in ACC.
  • Contrast-enhanced ultrasound has been shown to have a high sensitivity and specifity for the differentiation of hepatic and neuroendocrine tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Contrast Media / pharmacology. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425368.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


82. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M, Toscano V: Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr Relat Cancer; 2008 Mar;15(1):1-10
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
  • Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chloro-phenyl) ethane (o,p'-DDD), is a compound that represents the effective agent in the treatment of the adrenocortical carcinoma (ACC), able to block cortisol synthesis.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Antineoplastic Agents, Hormonal / pharmacology. Biomarkers, Tumor / metabolism. Mitotane / pharmacology. Neoplasm Proteins / metabolism. Proteomics
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Electrophoresis, Gel, Two-Dimensional. Humans. Hydrocortisone / metabolism. Mitochondria / drug effects. Mitochondria / metabolism. Progesterone / metabolism. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Testosterone / metabolism. Tumor Cells, Cultured / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. MITOTANE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310271.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 3XMK78S47O / Testosterone; 4G7DS2Q64Y / Progesterone; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


83. Li D, Mukai K, Suzuki T, Suzuki R, Yamashita S, Mitani F, Suematsu M: Adrenocortical zonation factor 1 is a novel matricellular protein promoting integrin-mediated adhesion of adrenocortical and vascular smooth muscle cells. FEBS J; 2007 May;274(10):2506-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical zonation factor 1 is a novel matricellular protein promoting integrin-mediated adhesion of adrenocortical and vascular smooth muscle cells.
  • Expression of a previously cloned secretory protein named adrenocortical zonation factor 1 (AZ-1, also called Tin-ag-RP or lipocalin 7) is tightly linked with the zonal differentiation of adrenocortical cells.
  • In this study, the location of AZ-1 was specified to the basal laminae along adrenocortical sinusoidal capillaries and surrounding VSM cells in the arterial system, consistent with the fact that AZ-1 was extractable under denaturing conditions as a 52 kDa polypeptide.
  • AZ-1 immobilized on substratum or bound to collagens or anastellin promoted adhesion and spreading of adrenocortical cells.
  • Collectively with the putative role of AZ-1 in the adrenocortical zonation, we propose that AZ-1 potentially regulates functions of adrenocortical and VSM cells by modulating cell-matrix interactions.
  • [MeSH-major] Adrenal Cortex / cytology. Carrier Proteins / physiology. Cell Adhesion / physiology. Integrins / physiology. Muscle, Smooth, Vascular / cytology. Neoplasm Proteins / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425658.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Fibronectins; 0 / Integrin alpha1beta1; 0 / Integrin alpha2beta1; 0 / Integrin alpha5beta1; 0 / Integrins; 0 / Lipocalins; 0 / Neoplasm Proteins; 0 / Tinagl protein, mouse; 9007-34-5 / Collagen
  •  go-up   go-down


84. Sasaki K, Desimone M, Rao HR, Huang GJ, Seethala RR: Adrenocortical carcinosarcoma: a case report and review of the literature. Diagn Pathol; 2010;5:51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinosarcoma: a case report and review of the literature.
  • Adrenocortical carcinosarcoma is an extremely rare and aggressive variant of adrenocortical carcinoma characterized by the presence of both carcinomatous and sarcomatous components, with the latter often showing heterologous differentiation.
  • In order to increase awareness and identify potential diagnostic pitfalls, we report the ninth case of non-functioning adrenocortical carcinosarcoma in a 45-year-old man who presented with worsening epigastric pain and a left large retroperitoneal mass in close proximity to the body/tail of pancreas and third portion of the duodenum with displacement of the kidney without parenchymal invasion and multiple liver nodules detected by computed tomographic scan.
  • On en bloc resection, the tumor grossly did not involve the pancreas, kidney or colon.
  • Histologically, the tumor was composed of two distinct components - an epithelioid component with granular cytoplasm that stained for synaptophysin, Melan-A, calretinin, and vimentin compatible with adrenocortical differentiation, and a pleomorphic to spindled component that was positive for desmin and myogenin, compatible with rhabdomyosarcomatous differentiation.
  • A wedge biopsy of a liver nodule showed morphologic features similar to the epithelial component of the primary tumor.
  • Adrenocortical carcinosarcoma is a rare malignancy that adds to the differential diagnostic considerations for a retroperitoneal epithelioid malignancy.
  • Awareness of this as a possibility will help in distinguishing this tumor from other carcinomas, melanomas, and true sarcomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Carcinosarcoma / pathology
  • [MeSH-minor] Adrenalectomy. Biomarkers, Tumor / analysis. Biopsy. Fatal Outcome. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52 [16280664.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1987 Feb;88(2):231-8 [3574283.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):19-28 [3354641.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(2):161-7 [2472700.001]
  • [Cites] J Surg Oncol. 1990 Oct;45(2):134-6 [2214792.001]
  • [Cites] Lab Invest. 1992 Feb;66(2):169-74 [1735954.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):626-31 [1599039.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):941-5 [8352379.001]
  • [Cites] Pathology. 1996 Nov;28(4):298-305 [9007945.001]
  • [Cites] J Korean Med Sci. 1997 Aug;12(4):374-7 [9288640.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):516-24 [9647588.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] Arch Pathol Lab Med. 2006 Dec;130(12):1878-81 [17149968.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1356-62 [17721191.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1476-89 [17895748.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):215-9 [18080137.001]
  • [Cites] J Cutan Pathol. 2008 May;35(5):433-44 [18399807.001]
  • [Cites] Pathol Res Pract. 2010 Jan 15;206(1):59-65 [19369012.001]
  • [Cites] Int J Surg Pathol. 2010 Apr;18(2):103-20 [19124452.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Mar;10(1):67-70 [11893039.001]
  • (PMID = 20687934.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3224959
  •  go-up   go-down


85. Jarral OA, Todd C, Willson PD: Hemorrhagic shock secondary to spontaneous rupture of a non-secretory adrenal cortical tumour: A case report. Can Urol Assoc J; 2010 Dec;4(6):E161-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic shock secondary to spontaneous rupture of a non-secretory adrenal cortical tumour: A case report.
  • After emergency laparotomy, angiography, embolisation and histological investigation, a diagnosis of spontaneous rupture of a benign non-secretory adrenal cortical tumour was made.
  • To our knowledge, this is the only reported case of this diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2007 Jul;194(1):77-8 [17560914.001]
  • [Cites] J Surg Oncol. 2005 Apr 1;90(1):31-5 [15786413.001]
  • [Cites] Radiat Med. 2003 Sep-Oct;21(5):214-9 [14632297.001]
  • [Cites] Endocr J. 2001 Dec;48(6):691-6 [11873868.001]
  • [Cites] J Urol. 1992 Feb;147(2):311-8 [1346277.001]
  • (PMID = 21749812.001).
  • [ISSN] 1920-1214
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3038376
  •  go-up   go-down


86. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M: Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab; 2005 Mar;90(3):1332-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
  • In the present study, we evaluated PPARgamma mRNA and protein expression in tissue samples of human adrenocortical carcinomas (ACCs), normal adrenal glands, and the human ACC cell line H295R.
  • PPARgamma mRNA was expressed in six of eight ACC, two of three normal adrenal glands and the H295R cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Hypoglycemic Agents / pharmacology. Thiazolidinediones / pharmacology
  • [MeSH-minor] Adrenal Glands / cytology. Adrenal Glands / pathology. Adult. Aged. Cell Division / drug effects. Cell Line, Tumor. Female. Humans. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Neoplasm Invasiveness. PPAR gamma / genetics. PPAR gamma / metabolism. RNA, Messenger / analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. PIOGLITAZONE .
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585569.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; EC 3.4.24.24 / Matrix Metalloproteinase 2; X4OV71U42S / pioglitazone
  •  go-up   go-down


87. Wen MJ, Lin YF, Chen JS: Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression. Int J Urol; 2008 Jun;15(6):540-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly developed hypertension as an early marker of recurrence of adrenocortical carcinoma with high renin expression.
  • Adrenocortical carcinoma can recur frequently after successful surgery but no adequate markers can detect this recurrence.
  • Here, we present a recurrence of adrenocortical carcinoma with a high renin expression, after successful surgery, where hypertension has developed again.
  • Tumor recurrence was observed via (18)F-fluorodeoxyglucose positron emission tomography and coregistered computed tomography.
  • Based on our findings, follow-up blood pressure assessment may effectively predict the recurrence of adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / complications. Adrenocortical Carcinoma / metabolism. Hypertension / etiology. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / metabolism. Renin / biosynthesis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489644.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 3.4.23.15 / Renin
  •  go-up   go-down


88. Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Saeger W, Sbiera S, Schmull S, Voelker HU, Ströbel P, Allolio B, Fassnacht M: Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol; 2010 Dec;23(12):1596-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.
  • Adrenocortical carcinoma is a rare but highly malignant neoplasm with still limited treatment options.
  • Epidermal growth factor receptor (EGFR) has been shown to be overexpressed in many solid tumors, but its expression in adrenocortical carcinoma has been studied only in a limited number of cases.
  • Therefore, we analyzed the expression of EGFR in 169 adrenocortical carcinoma samples and compared it with 31 adrenocortical adenomas.
  • Additionally, in 30 cases of adrenocortical carcinoma, exons 18-21 of the EGFR gene were cloned and sequenced.
  • EGFR expression was found in 128 of 169 adrenocortical carcinoma samples (76%), and in 60 of these samples (=36%) strong membrane staining was detected.
  • In contrast, only 1 out of 31 adrenocortical adenomas weakly expressed the EGFR (3%).
  • In summary, EGFR was overexpressed in more than three-quarters of adrenocortical carcinoma cases of this series.
  • As EGFR is hardly expressed in adrenocortical adenomas, our results suggest that its expression in adrenocortical tumors indicates a malignant phenotype, which may be used in the differential diagnosis between adrenocortical adenomas and carcinomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / metabolism. Adrenocortical Adenoma / pathology. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693985.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


89. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol; 2009 Mar 1;27(7):1108-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.
  • PURPOSE: Adrenocortical tumors, especially cancers, remain challenging both for their diagnosis and prognosis assessment.
  • PATIENTS AND METHODS: One hundred fifty-three unilateral adrenocortical tumors were studied by microarray (n = 92) or reverse transcription quantitative polymerase chain reaction (n = 148).
  • A two-gene predictor of malignancy was built using the disease-free survival as the end point in a training cohort (n = 47), then validated in an independent validation cohort (n = 104).
  • Similarly, for malignant tumors, a two-gene predictor of survival was built using the overall survival as the end point in a training cohort (n = 23), then tested in an independent validation cohort (n = 35).
  • RESULTS: Unsupervised clustering analysis discriminated robustly the malignant and benign tumors, and identified two groups of malignant tumors with very different outcome.
  • The combined expression of DLG7 and PINK1 was the best predictor of disease-free survival (log-rank P approximately 10(-12)), could overcome the uncertainties of intermediate pathological Weiss scores, and remained significant after adjustment to the Weiss score (P < 1.3 x 10(-2)).
  • Among the malignant tumors, the combined expression of BUB1B and PINK1 was the best predictor of overall survival (P < 2 x 10(-6)), and remained significant after adjusting for MacFarlane staging (P < .005).
  • CONCLUSION: Gene expression analysis unravels two distinct groups of adrenocortical carcinomas.
  • The molecular predictors of malignancy and of survival are reliable and provide valuable independent information in addition to pathology and tumor staging.
  • These original tools should provide important improvements for adrenal tumors management.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Biomarkers, Tumor / genetics. Neoplasm Proteins / genetics. Protein Kinases / genetics. Protein-Serine-Threonine Kinases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cluster Analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Proportional Hazards Models. Prospective Studies. Reproducibility of Results. Survival Analysis

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLGAP5 protein, human; 0 / Neoplasm Proteins; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / PTEN-induced putative kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


90. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer; 2009 Sep;16(3):919-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
  • Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status.
  • Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value.
  • Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands.
  • GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands.
  • When analysing patients in their early stages and advanced disease separately, similar results were obtained.
  • HR for survival was 5.31 (1.80-15.62) in patients with metastatic ACC and in patients after radical resection the HR for disease-free survival was 6.10 (2.16-16.94).
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / metabolism. Glucose Transporter Type 1 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Glucose / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465749.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose
  •  go-up   go-down


91. Parmar J, Key RE, Rainey WE: Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J Clin Endocrinol Metab; 2008 Nov;93(11):4542-6
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line.
  • CONTEXT: The molecular mechanisms regulating adrenal steroidogenesis continue to be defined.
  • The only current human adrenocortical cell line is the NCI-H295 and its substrains.
  • An ACTH-responsive human adrenocortical model would add significantly to studies directed at defining the molecular control of corticosteroid biosynthesis.
  • OBJECTIVE: The objective of the study was to develop a human adrenal cell line that retained both Ang II- and ACTH-regulated corticosteroid production.
  • DESIGN: Human adrenocortical carcinoma (HAC) cells were isolated from an adrenal tumor removed from a girl presenting with virilization and hypertension.
  • CONCLUSION: The current study describes the development and characterization of an ACTH- and Ang II-responsive human adrenal cell line.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocorticotropic Hormone / physiology. Hydrocortisone / biosynthesis
  • [MeSH-minor] Aldosterone / biosynthesis. Angiotensin II / pharmacology. Cell Line, Tumor. Child. Cholesterol Side-Chain Cleavage Enzyme / genetics. Colforsin / pharmacology. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Receptor, Melanocortin, Type 2 / genetics. Reverse Transcriptase Polymerase Chain Reaction. Steroid 17-alpha-Hydroxylase / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):38097-106 [10608879.001]
  • [Cites] Endocrinology. 2008 Apr;149(4):1898-905 [18174287.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):941-51 [11196473.001]
  • [Cites] Mol Endocrinol. 2001 Aug;15(8):1277-93 [11463853.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4285-8 [12959982.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1144-57 [14988427.001]
  • [Cites] J Biol Chem. 2004 Sep 3;279(36):37622-30 [15208301.001]
  • [Cites] Methods Enzymol. 1979;58:570-4 [423792.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5488-96 [2386954.001]
  • [Cites] Mol Endocrinol. 1993 Mar;7(3):423-33 [8387159.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):731-7 [8396576.001]
  • [Cites] Endocrinology. 1993 Oct;133(4):1555-61 [8404594.001]
  • [Cites] Mol Cell Endocrinol. 1994 Feb;99(1):R17-20 [8187950.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5677-84 [7588323.001]
  • [Cites] Mol Endocrinol. 1997 May;11(5):638-49 [9139807.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1592-7 [9589661.001]
  • [Cites] Mol Cell Endocrinol. 2004 Dec 30;228(1-2):23-38 [15541570.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1805-18 [16439455.001]
  • [Cites] J Mol Endocrinol. 2007 Dec;39(6):365-74 [18055484.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):549-57 [11196427.001]
  • (PMID = 18713819.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Melanocortin, Type 2; 11128-99-7 / Angiotensin II; 1F7A44V6OU / Colforsin; 4964P6T9RB / Aldosterone; 9002-60-2 / Adrenocorticotropic Hormone; EC 1.14.15.6 / Cholesterol Side-Chain Cleavage Enzyme; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC2582572
  •  go-up   go-down


92. Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM: Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol; 2009 Jun;218(2):232-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma.
  • Gene array studies indicated that osteopontin (OPN) mRNA is highly expressed in adrenocortical carcinomas (ACCs).
  • In this study, we demonstrated OPN and integrin alphavbeta3 expression in normal adrenal glands and benign adenomas, with staining seen exclusively in adrenocortical cells as well as even stronger staining in ACC.
  • However, no association with survival was seen in Kaplan-Meier analysis including 111 patients with primary tumours graded for OPN staining and follow-up data available.
  • In conclusion, our in vitro data indicate that OPN and integrin alphavbeta3 may act as a functional complex facilitating the invasiveness of adrenocortical tumours.
  • This relationship remains of relevance to our understanding of carcinogenesis, but further studies are needed to address the physiological and pathological function of OPN in adrenal tissue.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Osteopontin / analysis
  • [MeSH-minor] Adenoma / chemistry. Adrenal Glands / chemistry. Blotting, Western / methods. Cell Line, Tumor. Gene Expression Profiling. Humans. Immunohistochemistry. Integrin alphaVbeta3 / analysis. Integrin alphaVbeta3 / genetics. Integrin alphaVbeta3 / metabolism. Kaplan-Meier Estimate. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transfection / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19326399.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 106441-73-0 / Osteopontin
  •  go-up   go-down


93. Leboulleux S, Dromain C, Bonniaud G, Aupérin A, Caillou B, Lumbroso J, Sigal R, Baudin E, Schlumberger M: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab; 2006 Mar;91(3):920-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography.
  • OBJECTIVE: Patients with adrenocortical cancer are submitted to multiple imaging procedures for diagnosis of recurrence and staging.
  • METHODS: Twenty-eight consecutive patients with adrenocortical cancer referred from November 2003 to December 2004 to the Institut Gustave Roussy were included.
  • The sensitivities for the detection of distinct lesions and the diagnosis of metastatic organs were 90 and 93% for PET/CT and 88 and 82% for TAP-CT, respectively.
  • Tumor size and mitotic rate were significantly associated with FDG uptake.
  • CONCLUSIONS: We show that FDG-PET/CT is complementary to TAP-CT and of special interest in the diagnosis of local relapses.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiography. Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368753.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Jain M, Kapoor S, Mishra A, Gupta S, Agarwal A: Weiss criteria in large adrenocortical tumors: a validation study. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):222-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weiss criteria in large adrenocortical tumors: a validation study.
  • BACKGROUND: Several systems including pathologic criteria alone or in combination with clinical features have been proposed to differentiate between benign and malignant adrenocortical tumors and assess their prognosis.
  • Since we see large adrenocortical carcinoma (ACC), we attempt to evaluate the diagnostic power of Weiss system in large ACC.
  • MATERIALS AND METHODS: In this study clinicopathological characteristics of 42 adrenocortical neoplasms are studied and classified into adrenocortical adenoma (ACA) and ACC based on Weiss score of less than or equal to three or greater than three.
  • RESULTS: The histological criteria of Weiss appeared to predict tumor prognosis accurately.
  • CONCLUSION: Weiss score was found to be a good prognostic factor for tumors of the adrenal cortex.
  • [MeSH-major] Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / pathology. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / pathology. Histocytochemistry / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Middle Aged. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551521.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


95. Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, Berruti A, Terzolo M: Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol; 2010 May;57(5):873-8
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.
  • BACKGROUND: Although there is consensus that laparoscopy is the standard of care for the resection of benign adrenal tumours, there is controversy regarding the role of laparoscopy for the resection of adrenocortical cancer (ACC).
  • OBJECTIVE: The aim of the present study was to review the ACC database of the San Luigi Hospital to compare the oncologic effectiveness of open adrenalectomy (OA) versus laparoscopic adrenalectomy (LA) in the treatment of patients with stage I and II ACC.
  • The "open group" consisted of patients treated with OA; the "lap group" consisted of patients treated with LA.
  • MEASUREMENTS: Oncologic effectiveness of the procedures was tested comparing the recurrence-free survival of patients treated with OA versus LA.
  • CONCLUSIONS: The present findings provide interesting evidence that OA and LA may be comparable in terms of recurrence-free survival for patients with stage I and II ACC when the principles of surgical oncology are respected.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20137850.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Nakamura M, Miki Y, Akahira J, Morimoto R, Satoh F, Ishidoya S, Arai Y, Suzuki T, Hayashi Y, Sasano H: An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol; 2009;20(1):17-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.
  • Adrenocortical carcinoma (ACC) is a rare neoplasm but some of the cases are highly malignant.
  • However, these therapies are only effective in the cases in which corresponding targets are expressed in tumor tissues.
  • Therefore, we evaluated expression of potential surrogate markers using immunohistochemistry in archival materials of adrenocortical carcinoma in order to explore the potential application of target specific therapies in ACC in this study.
  • We immunolocalized ten established or potential surrogate markers of target-specific therapies, located in the Ras/extracellular signal-regulated kinase and phosphatidylinositol-3 kinase/Akt pathways, in 41 ACC cases, 54 adrenocortical adenoma (ACA) cases, and five nonpathological adrenal glands and correlated the findings with clinicopathological factors of the patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers, Tumor / analysis. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adolescent. Adrenocortical Adenoma. Adult. Aged. Child. Child, Preschool. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Oct 11;26(46):6577-92 [17486079.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6518-26 [17975165.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):290-4 [16376541.001]
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):48-56 [16458846.001]
  • [Cites] FEBS J. 2005 Aug;272(16):4211-20 [16098202.001]
  • [Cites] Mod Pathol. 1994 Sep;7(7):741-6 [7824507.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1168-71 [11948129.001]
  • [Cites] Pathol Oncol Res. 2006;12(4):243-6 [17189989.001]
  • [Cites] Trends Biochem Sci. 2004 May;29(5):233-42 [15130559.001]
  • [Cites] Eur J Endocrinol. 2004 Mar;150(3):345-9 [15012620.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):785-91 [17848913.001]
  • [Cites] Oncology. 2003;64(1):61-73 [12457033.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1060-5 [9569040.001]
  • [Cites] BMC Cancer. 2007 Aug 08;7:153 [17686164.001]
  • [Cites] Ann Neurol. 2004 Oct;56(4):510-9 [15455398.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12 ):3577-84 [17575221.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] J Urol. 2007 Jan;177(1):346-52 [17162089.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):120-39 [16889899.001]
  • [Cites] Drugs. 2007;67(14):2045-75 [17883287.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S18-23 [17686441.001]
  • [Cites] Virchows Arch. 2007 Feb;450(2):151-9 [17149612.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):455-60; discussion 460-1 [7725728.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Endocr Pathol. 2006 Winter;17 (4):345-54 [17525483.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):807-26 [11297505.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] Ann Clin Lab Sci. 2006 Summer;36(3):283-93 [16951269.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6416-22 [17041626.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2610-6 [15805257.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):4964-73 [17785546.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 19184558.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


97. Aspinall SR, Imisairi AH, Bliss RD, Scott-Coombes D, Harrison BJ, Lennard TW: How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl; 2009 Sep;91(6):489-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How is adrenocortical cancer being managed in the UK?
  • INTRODUCTION: Adrenocortical carcinomas are rare.
  • This case series is reported to give an overview of how adrenocortical carcinoma is currently managed in the UK.
  • PATIENTS AND METHODS: A retrospective review was made of case notes from patients with adrenocortical carcinomas presenting to the authors (TWJL, RDB, BJH, and DS-C) over the past 10 years in Newcastle, Sheffield and Cardiff.
  • All tumours were greater than 5 cm in diameter.
  • CONCLUSIONS: The size of tumour, stage and mode of presentation, age and overall survival of patients in this study are comparable to published series of adrenocortical carcinomas from major endocrine surgical centres world-wide.
  • The exact role of adjuvant therapy in the management of adrenocortical carcinoma is not as well established as for other more common malignancies.
  • Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Adrenalectomy / methods. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cytotoxins / therapeutic use. Great Britain. Humans. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2001 Jan;57(1):176-82 [11164177.001]
  • [Cites] Arch Pathol (Chic). 1949 Nov;48(5):387-94 [18143915.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1113-21 [11571723.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Surgery. 1992 Dec;112(6):972-9; discussion 979-80 [1455322.001]
  • [Cites] J Pharm Sci. 1995 Feb;84(2):134-8 [7738789.001]
  • [Cites] Radiology. 1995 Nov;197(2):411-8 [7480685.001]
  • [Cites] Surgery. 1996 Feb;119(2):161-70 [8571201.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jul;171(1):201-4 [9648789.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):718-26 [15581542.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4 [16895957.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2415-8 [17554125.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • (PMID = 19558758.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cytotoxins; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2966201
  •  go-up   go-down


98. Stephenson TJ: Prognostic and predictive factors in endocrine tumours. Histopathology; 2006 May;48(6):629-43
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive factors in endocrine tumours.
  • This review encompasses the diagnostic features of malignancy, the routinely observable prognostic features and the prognostic and predictive features emerging from research techniques in the principal endocrine neoplasms: pancreatic and extrapancreatic endocrine cell tumours, thyroid and parathyroid neoplasia, adrenal cortical neoplasms and adrenal and extra-adrenal paragangliomas.
  • While each endocrine tissue has its own set of diagnostic features for malignancy, and prognostic features once a diagnosis of malignancy has been established, there are a few common themes.
  • For several endocrine neoplasms, definite recognition of malignancy can be difficult and may depend upon frank invasive or metastatic growth at presentation.
  • The accurate documentation of routinely observable histological features interpreted in the light of current literature has not been superseded by special techniques in the statement of diagnosis or prognosis in the vast majority of endocrine neoplasms.
  • [MeSH-major] Endocrine Gland Neoplasms / pathology. Peptide Hormones / analysis
  • [MeSH-minor] Diagnosis, Differential. Glucagon / analysis. Humans. Insulin / analysis. Predictive Value of Tests. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681678.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Peptide Hormones; 9007-92-5 / Glucagon
  • [Number-of-references] 123
  •  go-up   go-down


99. Collins BR: Endocrine diseases of rodents. Vet Clin North Am Exot Anim Pract; 2008 Jan;11(1):153-62, vii-viii
MedlinePlus Health Information. consumer health - Pet Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical diagnosis of endocrine diseases almost never occurs in free-ranging animals in their native habitat.
  • Feral animals that have clinical endocrine disease, such as neoplasia, adrenal cortical hyperplasia, or diabetes, would exhibit clinical signs of altered behavior that would result in their removal by predators.
  • The diagnosis of endocrine disease thus takes place in the relatively protective environment of captivity.
  • [MeSH-major] Animals, Domestic. Endocrine System Diseases / veterinary. Rodent Diseases / diagnosis
  • [MeSH-minor] Animals. Cricetinae. Diagnosis, Differential. Female. Gerbillinae. Guinea Pigs. Male. Mice. Rats. Rodentia. Species Specificity

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165143.001).
  • [ISSN] 1094-9194
  • [Journal-full-title] The veterinary clinics of North America. Exotic animal practice
  • [ISO-abbreviation] Vet Clin North Am Exot Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


100. Komorowski J, Jurczynska J, Stepien T, Kolomecki K, Kuzdak K, Stepien H: Serum concentrations of TNF α and its soluble receptors in patients with adrenal tumors treated by surgery. Int J Mol Sci; 2010;11(6):2281-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum concentrations of TNF α and its soluble receptors in patients with adrenal tumors treated by surgery.
  • The peripheral blood levels of TNF alpha and its soluble receptors were studied in 39 patients with malignant and benign adrenal tumors treated by adrenalectomy.
  • The concentrations of TNF alpha were significantly elevated in patients with malignant tumors of the adrenal cortex and in patients with Conn's syndrome compared to control.
  • After adrenalectomy, the levels of TNF alpha were decreased in patients with malignant tumors and in patients with Conn's syndrome, nonfunctioniong adenomas and pheochromocytomas compared to the concentration before surgery.
  • However, to confirm practicality of the evaluation of TNF alpha and its soluble receptors in differential diagnosis in patients with adrenal tumors, a larger study group is needed.
  • [MeSH-major] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / surgery. Receptors, Tumor Necrosis Factor / blood. Tumor Necrosis Factor-alpha / blood
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Receptors, Tumor Necrosis Factor, Type I / blood. Receptors, Tumor Necrosis Factor, Type II / blood

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gen Comp Endocrinol. 2000 May;118(2):249-61 [10890565.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):110-3 [10689296.001]
  • [Cites] Br J Pharmacol. 2002 Feb;135(4):855-75 [11861313.001]
  • [Cites] Cell Signal. 2002 Jun;14(6):477-92 [11897488.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Mar 30;143(3):997-1004 [2436621.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):630-2 [2443857.001]
  • [Cites] Science. 1990 May 25;248(4958):1019-23 [2160731.001]
  • [Cites] Leukemia. 1991 Jan;5(1):32-5 [1999955.001]
  • [Cites] Immunol Today. 1991 May;12(5):141-2 [1652255.001]
  • [Cites] Cytokine. 1990 Jul;2(4):231-7 [1966549.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):323-9 [1310100.001]
  • [Cites] J Reprod Immunol. 1992 Aug;22(2):105-16 [1323674.001]
  • [Cites] Hepatology. 1992 Sep;16(3):749-55 [1324217.001]
  • [Cites] Clin Exp Immunol. 1992 Sep;89(3):351-5 [1325303.001]
  • [Cites] Tidsskr Nor Laegeforen. 1992 Nov 20;112(28):3545-7 [1334285.001]
  • [Cites] Oncology. 1994 Mar-Apr;51(2):142-53 [8196898.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1492-7 [7962348.001]
  • [Cites] Annu Rev Immunol. 1995;13:307-38 [7612226.001]
  • [Cites] Melanoma Res. 1995 Aug;5(4):235-42 [7496158.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):807-13 [8636308.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1397-411 [8879212.001]
  • [Cites] Endocr Res. 1996 Nov;22(4):867-73 [8969952.001]
  • [Cites] J Drug Target. 1998;5(6):403-13 [9783674.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8 [9815646.001]
  • [Cites] Curr Opin Immunol. 1999 Jun;11(3):340-5 [10465590.001]
  • [Cites] Endokrynol Pol. 2006 Nov-Dec;57(6):633-40 [17253437.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2422-8 [17438101.001]
  • [Cites] Front Biosci. 2008;13:2774-83 [17981752.001]
  • [Cites] J Immunol. 2008 Oct 1;181(7):4461-70 [18802049.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 28;376(4):748-52 [18814840.001]
  • [Cites] Neoplasma. 2009;56(1):56-62 [19152246.001]
  • [Cites] Endokrynol Pol. 2009 Jan-Feb;60(1):9-13 [19224499.001]
  • [Cites] Infect Immun. 2001 Nov;69(11):6881-6 [11598062.001]
  • (PMID = 20640152.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2904916
  • [Keywords] NOTNLM ; TNF α / TNF α R1 / TNF α R2 / adrenal tumors / adrenalectomy
  • [General-notes] NLM/ Original DateCompleted: 20110714
  •  go-up   go-down






Advertisement